

## Administrative Record Index

Letter from Charles Ryan, Director, Arizona Department of Corrections, to David Thomas, FDA Investigations, re: Inspection and Release of Entry #574-0251126-5, Thiopental Sodium	11/10/2010	000027
Letter from Dale Baich, Supervisor, Capital Habeas Unit, Office of the Federal Public Defender for the District of Arizona, to Thomas Emerick, Assistant Special Agent in Charge, FDA	11/17/2010	000028-000029
Department of Treasury Entry/Immediate Delivery Form	11/24/2010	000030-000031
FDA's OASIS Screenshot for Entry # 112-9938358-2	n/a	000032
Letter from Benjamin Rice, General Counsel, State of California, to Ruth Dixon, FDA	12/9/2010	000033
Sodium Thiopental Statement, Key Messages	12/29/2010	000034-000035
Email from Shelly Burgess to Nathan Koppel	1/4/2011	000036-000037
Letter from Coleen Klasmeier, Bradford Berenson (Sidley Austin), and Dale Baich (Office of the Federal Public Defender for the District of Arizona), to Margaret Hamburg, Commissioner, FDA	1/4/2011	000038-000050
Guidance for handling pending and future shipments of Sodium Thiopental	1/5/2011	000051-000057
Notice of FDA Action	1/6/2011	000058-000059
Notice of FDA Action	1/7/2011	000060-000061
Letter from Patricia Shafer, Acting District Director, New Orleans District Office, to Benjamin Rice, Chief Counsel, California Department of Corrections & Rehabilitation	1/7/2011	000062-000063
Letter from Alonza Cruse, District Director, Los Angeles District, to Carson McWilliams, Warden, Arizona State Prison Complex	n/a	000064
<b>Miscellaneous</b>		
FDA Establishment Inspection Report for Sandoz - Endorsement Excerpt	7/8/2009	000065
FDA Establishment Inspection Report for Sandoz - Summary Excerpt	7/29/2010	000066-000069
Form FDA 483 - Inspectional Observations for Sandoz	7/29/2010	000070

**Ramos, Merly**

---

**From:** Lumpkin, Murray  
**Sent:** Tuesday, November 16, 2010 2:03 PM  
**To:** 'tom.smith@bis.gsi.gov.uk'  
**Cc:** Sharfstein, JM; Hamburg, Margaret  
**Subject:** Substantive response from US FDA re: Sodium Thiopental

Dear Mr. Smith,

Thank you for your understanding and for your original inquiry. I do now have information that I hope will still be responsive to your time frame.

You asked for the "authoritative view from the FDA on the current usage of sodium thiopental for medical reasons within the United States.". Currently there is no sodium thiopental for sale in the United States, because the domestically manufactured supply has been unavailable for more than a year. There are no approved or permitted foreign sources of sodium thiopental. As a result, there is currently little to no current usage of sodium thiopental for medical reasons.

To your specific questions:

a) The question is whether it continues to be licensed for use within the US (and, if so, for what purposes);

There is no FDA-approved sodium thiopental for human use in the United States. Although the domestically manufactured supply is not approved, the product has been marketed and commercially available without FDA approval pursuant to FDA's Compliance Policy Guide on Marketed Unapproved Drugs. This document is available at:  
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070290.pdf>.

b) The question is whether it does in practice continue to be used. Even relatively low levels of usage (as a percentage of anaesthetic procedures) would be relevant information to us.

Currently, sodium thiopental's use is very limited due to the shortage described above. When there is no shortage, there is minimal use of sodium thiopental for medical reasons. Experts consulted by FDA have stated that sodium thiopental would be used in well under 5% of patients presenting for a general anesthetic. There is one scenario where the use of sodium thiopental would likely increase: if there were to be another shortage of propofol, an anesthetic agent. If propofol is in shortage, sodium thiopental would most likely find increased use as an induction agent for general anesthesia. Propofol is not currently in shortage in the United States.

Again, I hope this is responsive to your request

Sincerely,

Murray M. Lumpkin, M.D., M.Sc.  
Deputy Commissioner  
International Programs  
US Food and Drug Administration.

----- Original Message -----

From: Smith Tom (ITID) [mailto:tom.smith@bis.gsi.gov.uk]  
Sent: Tuesday, November 16, 2010 09:01 AM  
To: Lumpkin, Murray  
Subject: RE: Apologies: Sodium Thiopental

Dear Mr Lumpkin,

Thank you. I do understand and appreciate your efforts.

Tom Smith  
Head, Export Control Organisation  
Department for Business, Innovation and Skills  
3rd Floor, "Orchard 3", 1 Victoria Street

London SW1H 0ET  
Tel: 0207 215 4355  
Email: tom.smith@bis.gsi.gov.uk

The Department for Business, Innovation & Skills (BIS) is building a dynamic and competitive UK economy by creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this we will foster world-class universities and promote an open global economy. BIS - Investing in our future

-----Original Message-----

From: Lumpkin, Murray [mailto:Murray.Lumpkin@fda.hhs.gov]  
Sent: 16 November 2010 11:45  
To: Smith Tom (ITID)  
Cc: Sharfstein, JM; Hamburg, Margaret  
Subject: Apologies: Sodium Thiopental

Dear Mr Smith,  
I am writing today to offer my sincerest apologies that the US FDA has been unable to supply you with the information you requested in time to be of help in your UK exporting agency's trial tomorrow. I know it is now afternoon in London, and your trial starts tomorrow morning (London time). Even checking on an almost daily basis, as of this morning, I still have not received departmental clearance on a communication to you that would be responsive to your request. I know we have been singularly unhelpful, and, for that, I am truly sorry. I do wish we could have been more helpful to you. Again, many sincere apologies.

If I do happen to receive clearance later today our time, I will, of course, send you what is cleared in the hopes it might be of help, even at that late hour.

Best regards,  
Murray Lumpkin

Murray M. Lumpkin, MD, MSc  
Deputy Commissioner  
International Programs  
US Food and Drug Administration.

The original of this email was scanned for viruses by the Government Secure Intranet virus scanning service supplied by Cable&Wireless Worldwide in partnership with MessageLabs. (CCTM Certificate Number 2009/09/0052.) On leaving the GSi this email was certified virus free.

Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.

**Sodium Thiopental Statement, Key Messages**  
**December 29, 2010**

First, we would confirm the shipments are imported on or behalf of state correctional authorities.

Second, we would release the shipments with the following comment:

"FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity, or any other characteristics."

Third, we would use the following key messages and Q and A to respond to inquiries from the news media and other interested parties.

Key Messages

\*The U.S. Food and Drug Administration (FDA) is charged by Congress with protecting the public health. Ensuring the safety and effectiveness of pharmaceuticals used for medical purposes is a core part of FDA's mission.

\*Reviewing substances imported or used for the purpose of state-authorized lethal injection clearly falls outside of FDA's explicit public health role. FDA does not verify the identity, potency, safety, or effectiveness of substances imported for this purpose. FDA exercises similar enforcement discretion when these drugs are manufactured and purchased within the United States.

\*Accordingly, FDA chooses to continue to defer to law enforcement on all matters involving lethal injection, consistent with the U.S. Supreme Court's ruling in *Heckler v. Chaney* (1985).

Q and A

1.) What has happened so far this year with the imports of sodium thiopental?

In 2009 and 2010, FDA permitted the importation of several shipments of sodium thiopental to state Departments of Correction. In doing so, FDA deferred to law enforcement in the use of substances for lethal injection, which is consistent with the agency's longstanding policy. The agency did not conduct any review of these products for safety, effectiveness or quality.



2.) What has changed?

Two things. In the context of two death penalty cases in the fall of 2010, it was suggested that FDA "approves" the importation of these drugs for use in lethal injections and/or reviews them for safety, effectiveness, and quality. In actuality, the FDA neither approves nor reviews these drugs for use in lethal injections and feels it necessary to clear up any confusion. Also, FDA reviewed its procedures for the importation of sodium thiopental in concert with CBP. The agencies decided that since FDA does not conduct a review of pharmaceuticals intended for lethal injection, FDA will continue to exercise its enforcement discretion and defer to CBP's system for processing importations. The agencies are working together to develop a system for future shipments that avoids any confusion about whether FDA evaluates shipments of drugs intended for lethal injection.

3.) Is the importation of unapproved sodium thiopental for lethal injection illegal?

In deferring to law enforcement on matters involving pharmaceuticals for lethal injection, FDA is exercising enforcement discretion. This approach by the agency was upheld by the Supreme Court in *Heckler v. Chaney* (1985). Among the reasons cited by the Court for its decision not to review FDA's non-enforcement against lethal injection drugs is that agencies are responsible for prioritizing their enforcement resources to most effectively achieve their statutory missions. Again, FDA similarly defers to law enforcement with respect to transport of these substances within the United States.

4.) What will happen to any shipments that are currently pending?

FDA is releasing these with the comment: "FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity, or any other characteristics."

**Dohm, Julie**

---

**From:** Burgess, Shelly  
**Sent:** Tuesday, January 04, 2011 9:50 AM  
**To:** 'Koppel, Nathan'  
**Subject:** FW: update  
**Importance:** High

Nathan - As discussed, the following is the latest FDA position on sodium thiopental.

The U.S. Food and Drug Administration (FDA) is charged by Congress with protecting the public health. Ensuring the safety and effectiveness of pharmaceuticals used for medical purposes is a core part of FDA's mission.

Reviewing substances imported or used for the purpose of state-authorized lethal injection clearly falls outside of FDA's explicit public health role. FDA does not verify the identity, potency, safety, or effectiveness of substances imported for this purpose. FDA exercises similar enforcement discretion when these drugs are manufactured and purchased within the United States.

Accordingly, FDA chooses to continue to defer to law enforcement on all matters involving lethal injection, consistent with the U.S. Supreme Court's ruling in *Heckler v. Chaney* (1985).

**Following is information that addresses the import of sodium thiopental -**

So far this year with the imports of sodium thiopental, in 2009 and 2010, FDA permitted the importation of several shipments of sodium thiopental to state Departments of Correction. In doing so, FDA deferred to law enforcement in the use of substances for lethal injection, which is consistent with the agency's longstanding policy. The agency did not conduct any review of these products for safety, effectiveness or quality.

In the context of two death penalty cases in the fall of 2010, it was suggested that FDA "approves" the importation of these drugs for use in lethal injections and/or reviews them for safety, effectiveness, and quality. In actuality, the FDA neither approves nor reviews these drugs for use in lethal injections and feels it necessary to clear up any confusion. Also, FDA reviewed its procedures for the importation of sodium thiopental in concert with CBP. The agencies decided that since FDA does not conduct a review of pharmaceuticals intended for lethal injection, FDA will continue to exercise its enforcement discretion not to review these shipments and allow processing through CBP's automated system for importations. The agencies are working together to develop a system for future shipments that avoids any confusion about whether FDA evaluates shipments of drugs intended for lethal injection.

Is the importation of unapproved sodium thiopental for lethal injection illegal?

In deferring to law enforcement on matters involving pharmaceuticals for lethal injection, FDA is exercising enforcement discretion. This approach by the agency was upheld by the Supreme Court in *Heckler v. Chaney* (1985). Among the reasons cited by the Court for its decision not to review FDA's non-enforcement against lethal injection drugs is that agencies are responsible for prioritizing their enforcement resources to most effectively achieve their statutory missions. Again, FDA similarly defers to law enforcement with respect to transport of these substances within the United States.

What will happen to any shipments for correctional facilities that are currently pending?

FDA 000036

\*FDA is releasing these with the comment: "FDA releases this shipment, which is being imported by or on behalf of state correctional authorities. In keeping with established practice, FDA does not review or approve products for the purpose of lethal injection. FDA has not reviewed the products in this shipment to determine their identity, safety, effectiveness, purity, or any other characteristics."

I will try to find someone to speak with you. I hope this is helpful.

Best,  
Shelly

## Exhibit 15



*Goodman & Gilman's*  
The  
Pharmacological  
Basis of  
**THERAPEUTICS**

*eleventh edition*

**McGRAW-HILL**

MEDICAL PUBLISHING DIVISION

New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi  
San Juan Seoul Singapore Sydney Toronto

classes of anesthetics, as mutations in various regions (and subunits) of the GABA<sub>A</sub> receptor selectively affect the actions of various anesthetics (Belelli *et al.*, 1997; Krasowski and Harrison, 1999). Notably, none of the general anesthetics competes with GABA for its binding site on the receptor. The capacity of propofol and etomidate to inhibit the response to noxious stimuli is mediated by a specific site on the  $\beta_2$  subunit of the GABA<sub>A</sub> receptor (Jurd *et al.*, 2003), whereas the sedative effects of these anesthetics are mediated by the same site on the  $\beta_2$  subunit (Reynolds *et al.*, 2003). These results indicate that two components of anesthesia can be mediated by GABA<sub>A</sub> receptors; for anesthetics other than propofol and etomidate, which components of anesthesia are produced by actions on GABA<sub>A</sub> receptors remains a matter of conjecture.

Structurally closely related to the GABA<sub>A</sub> receptors are other ligand-gated ion channels including glycine receptors and neuronal nicotinic acetylcholine receptors. Glycine receptors may play a role in mediating inhibition by anesthetics of responses to noxious stimuli. Clinical concentrations of inhalational anesthetics enhance the capacity of glycine to activate glycine-gated chloride channels (glycine receptors), which play an important role in inhibitory neurotransmission in the spinal cord and brainstem. Propofol (Hales and Lambert, 1988), neurosteroids, and barbiturates also potentiate glycine-activated currents, whereas etomidate and ketamine do not (Mascia *et al.*, 1996). Subanesthetic concentrations of the inhalational anesthetics inhibit some classes of neuronal nicotinic acetylcholine receptors (Violet *et al.*, 1997; Flood *et al.*, 1997). However, these actions do not appear to mediate anesthetic immobilization (Eger *et al.*, 2002); rather, neuronal nicotinic receptors could mediate other components of anesthesia such as analgesia or amnesia.

The only general anesthetics that do not have significant effects on GABA<sub>A</sub> or glycine receptors are ketamine, nitrous oxide, cyclopropane, and xenon. These agents inhibit a different type of ligand-gated ion channel, the *N*-methyl-D-aspartate (NMDA) receptor (see Chapter 12). NMDA receptors are glutamate-gated cation channels that are somewhat selective for calcium and are involved in long-term modulation of synaptic responses (long-term potentiation) and glutamate-mediated neurotoxicity. Ketamine inhibits NMDA receptors by binding to the *phencyclidine* site on the NMDA receptor protein (Anis *et al.*, 1983), and the NMDA receptor is thought to be the principal molecular target for ketamine's anesthetic actions. Nitrous oxide (Mennerick *et al.*, 1998; Jevtovic-Todorovic *et al.*, 1998), cyclopropane (Raines *et al.*, 2001), and xenon (Franks *et al.*, 1998; de Sousa *et al.*, 2000) are potent and selective inhibitors of NMDA-activated currents, suggesting that these agents also may produce unconsciousness via actions on NMDA receptors.

Inhalational anesthetics have two other known molecular targets that may mediate some of their actions. Halogenated inhalational anesthetics activate some members of a class of K<sup>+</sup> channels known as two-pore domain channels (Gray *et al.*, 1998; Patel *et al.*, 1999); other two-pore domain channel family members are activated by xenon, nitrous oxide, and cyclopropane (Gruss *et al.*, 2004). These channels are important in setting the resting membrane potential of neurons and may be the molecular locus through which these agents hyperpolarize neurons. A second target is the molecular machinery involved in neurotransmitter release. In *Caenorhabditis elegans*, the action of inhalational anesthetics requires a protein complex (syntaxin, SNAP-25, synaptobrevin) involved in synaptic neurotransmitter release (van Swinderen *et al.*, 1999). These molecular interactions may explain in part the capacity of inhalational anesthetics to cause presynaptic inhibition in the hippocampus and could contribute to the amnesic effect of inhalational anesthetics.

**Summary.** Current evidence supports the view that most intravenous general anesthetics act predominantly through GABA<sub>A</sub> receptors and perhaps through some interactions with other ligand-gated ion channels. The halogenated inhalational agents have a variety of molecular targets, consistent with their status as complete (all components) anesthetics. Nitrous oxide, ketamine, and xenon constitute a third category of general anesthetics that are likely to produce unconsciousness via inhibition of the NMDA receptor and/or activation of two-pore-domain K<sup>+</sup> channels. The molecular mechanisms of general anesthetics are reviewed by Rudolph and Antkowiak (2004).

## PARENTERAL ANESTHETICS

### Pharmacokinetic Principles

Parenteral anesthetics are small, hydrophobic, substituted aromatic or heterocyclic compounds (Figure 13-1). Hydrophobicity is the key factor governing their pharmacokinetics (Shafer and Stanski, 1992). After a single intravenous bolus, these drugs preferentially partition into the highly perfused and lipophilic tissues of the brain and spinal cord where they produce anesthesia within a single circulation time. Subsequently blood levels fall rapidly, resulting in drug redistribution out of the CNS back into the blood. The anesthetic then diffuses into less perfused






Figure 13-1. Structures of parenteral anesthetics.



**Figure 13-2.** Thiopental serum levels after a single intravenous induction dose. Thiopental serum levels after a bolus can be described by two time constants,  $t_{1/2\alpha}$  and  $t_{1/2\beta}$ . The initial fall is rapid ( $t_{1/2\alpha} < 10$  min) and is due to redistribution of drug from the plasma and the highly perfused brain and spinal cord into less well-perfused tissues such as muscle and fat. During this redistribution phase, serum thiopental concentration falls to levels at which patients awaken (AL, awakening level; see inset—the average thiopental serum concentration in 12 patients after a 6-mg/kg intravenous bolus of thiopental). Subsequent metabolism and elimination is much slower and is characterized by a half-life ( $t_{1/2\beta}$ ) of more than 10 hours. (Adapted with permission from Burch and Stanski, 1983.)

tissues such as muscle and viscera, and at a slower rate into the poorly perfused but very hydrophobic adipose tissue. Termination of anesthesia after single boluses of parenteral anesthetics primarily reflects redistribution out of the CNS rather than metabolism (Figure 13-2). After redistribution, anesthetic blood levels fall according to a complex interaction between the metabolic rate and the amount and lipophilicity of the drug stored in the peripheral compartments (Hughes *et al.*, 1992; Shafer and Stanski, 1992). Thus, parenteral anesthetic half-lives are “context-sensitive,” and the degree to which a half-life is contextual varies greatly from drug to drug, as might be predicted based on their differing hydrophobicities and metabolic clearances (Table 13-2 and Figure 13-3). For example, after a single bolus of thiopental, patients usually emerge from anesthesia within 10 minutes; however, a patient may require more than a day to awaken from a prolonged thiopental infusion. Most individual variability in sensitivity to parenteral anesthetics can be accounted for by pharmacokinetic factors (Wada *et al.*, 1997). For



**Figure 13-3.** Context-sensitive half-time of general anesthetics. The duration of action of single intravenous doses of anesthetic/hypnotic drugs is similarly short for all and is determined by redistribution of the drugs away from their active sites (see Figure 13-2). However, after prolonged infusions, drug half-lives and durations of action are dependent on a complex interaction between the rate of redistribution of the drug, the amount of drug accumulated in fat, and the drug's metabolic rate. This phenomenon has been termed the *context-sensitive half-time*; that is, the half-time of a drug can be estimated only if one knows the context—the total dose and over what time period it has been given. Note that the half-times of some drugs such as etomidate, propofol, and ketamine increase only modestly with prolonged infusions; others (e.g., diazepam and thiopental) increase dramatically. (Reproduced with permission from Reves *et al.*, 1994.)

example, in patients with lower cardiac output, the relative perfusion of and fraction of anesthetic dose delivered to the brain is higher; thus, patients in septic shock or with cardiomyopathy usually require lower doses of anesthetic. The elderly also typically require a smaller anesthetic dose, primarily because of a smaller initial volume of distribution (Homer and Stanski, 1985). As described below, similar principles govern the pharmacokinetics of the hydrophobic inhalational anesthetics, with the added complexity of drug uptake by inhalation.

## SPECIFIC PARENTERAL AGENTS

### Barbiturates

**Chemistry and Formulations.** Anesthetic barbiturates are derivatives of barbituric acid (2,4,6-trioxohexahydropyrimidine), with either an oxygen or sulfur at the 2-position (Figure 13-1). The three barbiturates used for clinical anesthesia are *sodium thiopental*, *thia-*

**Table 13-2***Pharmacological Properties of Parenteral Anesthetics*

DRUG	FORMULATION	INDUCTION DOSE (mg/kg)	MINIMAL HYPNOTIC LEVEL (μg/ml)	INDUCTION DOSE DURATION (min)	$T_{1/2\beta}$ (hours)	CL (ml/min/kg)	PROTEIN BINDING (%)	$V_{ss}$ (L/kg)
Thiopental	25 mg/ml in aqueous solution + 1.5 mg/ml $\text{Na}_2\text{CO}_3$ ; pH = 10–11	3–5	15.6	5–8	12.1	3.4	85	2.3
Methohexital	10 mg/ml in aqueous solution + 1.5 mg/ml $\text{Na}_2\text{CO}_3$ ; pH = 10–11	1–2	10	4–7	3.9	10.9	85	2.2
Propofol	10 mg/ml in 10% soybean oil, 2.25% glycerol, 1.2% egg PL, 0.005% EDTA or 0.025% Na-MBS; pH = 4.5–7	1.5–2.5	1.1	4–8	1.8	30	98	2.3
Etomidate	2 mg/ml in 35% PG; pH = 6.9	0.2–0.4	0.3	4–8	2.9	17.9	76	2.5
Ketamine	10, 50, or 100 mg/ml in aqueous solution; pH = 3.5–5.5	0.5–1.5	1	10–15	3.0	19.1	27	3.1

SOURCES: Thiopental: Clarke *et al.*, 1968; Burch and Stanski, 1983; Hudson *et al.*, 1983; Hung *et al.*, 1992; methohexital: Brand *et al.*, 1963; Clarke *et al.*, 1968; Kay and Stephenson, 1981; Hudson *et al.*, 1983; McMurray *et al.*, 1986; propofol: Kirkpatrick *et al.*, 1988; Langley and Heel, 1988; Shafer *et al.*, 1988; etomidate: Doenicke, 1974; Meuldermans and Heykants, 1976; Fragen *et al.*, 1983; Hebron *et al.*, 1983; ketamine: Chang and Glazko, 1974; Clements and Nimmo, 1981; White *et al.*, 1982; Dayton *et al.*, 1983. ABBREVIATIONS:  $t_{1/2\beta}$ ,  $\beta$  phase half-life; CL, clearance;  $V_{ss}$ , volume of distribution at steady state; EDTA, ethylenediaminetetraacetic acid; Na-MBS, Na-metabisulfite; PG, propylene glycol; PL, phospholipid.



mylal, and methohexital. Sodium thiopental (PENTOTHAL) has been used most frequently for inducing anesthesia. The barbiturate anesthetics are supplied as racemic mixtures despite enantioselectivity in their anesthetic potency (Andrews and Mark, 1982). Barbiturates are formulated as the sodium salts with 6% sodium carbonate and reconstituted in water or isotonic saline to produce 1% (methohexital), 2% (thiamylal), or 2.5% (thiopental) alkaline solutions with pHs of 10 to 11. Once reconstituted, thiobarbiturates are stable in solution for up to 1 week, methohexital for up to 6 weeks if refrigerated. *Mixing with more acidic drugs commonly used during anesthetic induction can result in precipitation of the barbiturate as the free acid; thus, standard practice is to delay the administration of other drugs until the barbiturate has cleared the intravenous tubing.*

**Dosages and Clinical Use.** Recommended intravenous dosing for parenteral anesthetics in a healthy young adult is given in Table 13-2.

The typical induction dose (3 to 5 mg/kg) of thiopental produces unconsciousness in 10 to 30 seconds with a peak effect in 1 minute and duration of anesthesia of 5 to 8 minutes. Neonates and infants usually require a higher induction dose (5 to 8 mg/kg), whereas elderly and pregnant patients require less (1 to 3 mg/kg) (Homer and Stanski 1985; Jonmarker *et al.*, 1987; Gin *et al.*, 1997). Dosage calculation based on lean body mass reduces individual variation in dosage requirements. Doses can be reduced by 10% to 50% after premedication with benzodiazepines, opiates, or  $\alpha_2$  adrenergic agonists, because of their additive hypnotic effect (Short *et al.*, 1991; Nishina *et al.*, 1994; Wang *et al.*, 1996). Thiamylal is approximately equipotent with and in all aspects similar to thiopental. Methohexital (BREVITAL) is threefold more potent but otherwise similar to thiopental in onset and duration of action. Thiopental and thiamylal produce little to no pain on injection; methohexital elicits mild pain. Veno-irritation can be reduced by injection into larger non-hand veins and by prior intravenous injection of lidocaine (0.5 to 1 mg/kg). Intra-arterial injection of thiobarbiturates can induce a severe inflammatory and potentially necrotic reaction and should be avoided. Thiopental often evokes the taste of garlic just prior to inducing anesthesia. Methohexital and to a lesser degree the other barbiturates can produce excitement phenomena such as muscle tremor, hypertonus, and hiccups. For induction of pediatric patients without IV access, all three drugs can be given per rectum at approximately tenfold the IV dose.

**Pharmacokinetics and Metabolism.** Pharmacokinetic parameters for parenteral anesthetics are given in Table 13-2. As discussed above, the principal mechanism limiting anesthetic duration after single doses is redistribution of these hydrophobic drugs from the brain to other tissues. However, after multiple doses or infusions, the duration of action of the barbiturates varies considerably depending on their clearances.

Methohexital differs from the other two intravenous barbiturates in its much more rapid clearance; thus, it accumulates less during prolonged infusions (Schwilden and Stoekel, 1990). Because of their slow elimination and large volumes of distribution, prolonged infusions or very large doses of thiopental and thiamylal can pro-

duce unconsciousness lasting several days. Even single induction doses of thiopental and to a lesser degree methohexital can produce psychomotor impairment lasting up to 8 hours (Korttila *et al.*, 1975; Beskow *et al.*, 1995). Methohexital had been used frequently for outpatient procedures for which rapid return to an alert state is particularly desirable, but for this use it now has been largely replaced by propofol (*see below*). All three barbiturates are primarily eliminated by hepatic metabolism and renal excretion of inactive metabolites; a small fraction of thiopental undergoes desulfuration to the longer-acting hypnotic pentobarbital (Chan *et al.*, 1985). Each drug is highly protein bound (Table 13-2). Hepatic disease or other conditions that reduce serum protein concentration will decrease the volume of distribution and thereby increase the initial free concentration and hypnotic effect of an induction dose.

**Side Effects. Nervous System.** Besides producing general anesthesia, barbiturates reduce the cerebral metabolic rate, as measured by cerebral oxygen consumption ( $CMRO_2$ ), in a dose-dependent manner. Induction doses of thiopental reduce  $CMRO_2$  by 25% to 30% with a maximal decrease of 55% occurring at two to five times that dose (Stullken *et al.*, 1977). As a consequence of the decrease in  $CMRO_2$ , cerebral blood flow and intracranial pressure are similarly reduced (Shapiro *et al.*, 1973).

Because it markedly lowers cerebral metabolism, thiopental has been used as a protectant against cerebral ischemia. At least one human study suggests that thiopental may be efficacious in ameliorating ischemic damage in the perioperative setting (Nussmeier *et al.*, 1986). Thiopental also reduces intraocular pressure (Joshi and Bruce, 1975). Presumably in part due to their CNS depressant activity, barbiturates are effective anticonvulsants. Thiopental in particular is a proven medication in the treatment of status epilepticus (Modica *et al.*, 1990).

**Cardiovascular.** The anesthetic barbiturates produce dose-dependent decreases in blood pressure. The effect is due primarily to vasodilation, particularly venodilation, and to a lesser degree to a direct decrease in cardiac contractility. Typically, heart rate increases as a compensatory response to a lower blood pressure, although barbiturates also blunt the baroreceptor reflex.

Hypotension can be severe in patients with an impaired ability to compensate for venodilation such as those with hypovolemia, cardiomyopathy, valvular heart disease, coronary artery disease, cardiac tamponade, or  $\beta$  adrenergic blockade. Thiopental is not contraindicated in patients with coronary artery disease because the ratio of myocardial oxygen supply to demand appears to be adequately maintained within a patient's normal blood pressure range (Reiz *et al.*, 1981). None of the barbiturates has been shown to be arrhythmogenic.

**Respiratory.** Barbiturates are respiratory depressants. Induction doses of thiopental decrease minute ventilation and tidal volume with a smaller and inconsistent decrease in respiratory rate (Grounds *et al.*, 1987); reflex responses

to hypercarbia and hypoxia are diminished by anesthetic barbiturates (Hirshman *et al.*, 1975), and at higher doses or in the presence of other respiratory depressants such as opiates, apnea can result. With the exception of uncommon anaphylactoid reactions, these drugs have little effect on bronchomotor tone and can be used safely in asthmatics (Kingston and Hirshman, 1984).

**Other Side Effects.** Short-term administration of barbiturates has no clinically significant effect on the hepatic, renal, or endocrine systems. A single induction dose of thiopental does not alter tone of the gravid uterus, but may produce mild transient depression of newborn activity (Kosaka *et al.*, 1969). True allergies to barbiturates are rare (Baldo *et al.*, 1991); however, direct drug-induced histamine release is occasionally seen (Sprung *et al.*, 1997). Barbiturates can induce fatal attacks of porphyria in patients with acute intermittent or variegate porphyria and are contraindicated in such patients. Unlike inhalational anesthetics and succinylcholine, barbiturates and all other parenteral anesthetics apparently do not trigger malignant hyperthermia (Rosenberg *et al.*, 1997).

## Propofol

**Chemistry and Formulations.** Propofol now is the most commonly used parenteral anesthetic in the United States. The active ingredient in propofol, 2,6-diisopropylphenol, is essentially insoluble in aqueous solutions and is formulated only for IV administration as a 1% (10 mg/ml) emulsion in 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide. In the United States, disodium EDTA (0.05 mg/ml) or sodium metabisulfite (0.25 mg/ml) is added to inhibit bacterial growth. Nevertheless, significant bacterial contamination of open containers has been associated with serious patient infection; propofol should be either administered or discarded shortly after removal from sterile packaging.

**Dosage and Clinical Use.** The induction dose of propofol (DIPRIVAN) in a healthy adult is 1.5 to 2.5 mg/kg; propofol has an onset and duration of anesthesia similar to thiopental (Table 13-2). As with barbiturates, dosages should be reduced in the elderly and in the presence of other sedatives and increased in young children. Because of its reasonably short elimination half-life, propofol often is used for maintenance of anesthesia as well as for induction. For short procedures, small boluses (10% to 50% of the induction dose) every 5 minutes or as needed are effective. An infusion of propofol produces a more stable drug level (100 to 300  $\mu\text{g/kg}$  per minute) and is better suited for longer-term anesthetic maintenance. Infusion rates should be tailored to patient response and the levels of other hypnotics. Sedating doses of propofol are 20% to 50% of those required for general anesthesia. However, even at these lower doses, caregivers should be vigilant and prepared for all of the side effects of propofol discussed below, particularly airway obstruction and apnea. Propofol elicits pain on injection that can be reduced with

lidocaine and the use of larger arm and antecubital veins. Excitatory phenomena during induction with propofol occur at about the same frequency as with thiopental, but much less frequently than with methohexital (Langley and Heel, 1988).

**Pharmacokinetics and Metabolism.** The pharmacokinetics of propofol are governed by the same principles that apply to barbiturates. Onset and duration of anesthesia after a single bolus are similar to thiopental (Langley and Heel, 1988). Recovery after multiple doses or infusion has been shown to be much faster after propofol than after thiopental or even methohexital (Doze *et al.*, 1986; Langley and Heel, 1988).

Propofol's shorter duration after infusion can be explained by its very high clearance, coupled with the slow diffusion of drug from the peripheral to the central compartment (Figure 13-3). The rapid clearance of propofol explains its less severe hangover compared with barbiturates, and may allow for a more rapid discharge from the recovery room. Propofol is metabolized in the liver to less active metabolites that are renally excreted (Simons *et al.*, 1988); however, its clearance exceeds hepatic blood flow, and anhepatic metabolism has been demonstrated (Veroli *et al.*, 1992). Propofol is highly protein bound, and its pharmacokinetics, like those of the barbiturates, may be affected by conditions that alter serum protein levels (Kirkpatrick *et al.*, 1988).

**Side Effects. Nervous System.** The CNS effects of propofol are similar to those of barbiturates.

Propofol decreases CMRO<sub>2</sub>, cerebral blood flow, and intracranial and intraocular pressures by about the same amount as thiopental (Langley and Heel, 1988). Like thiopental, propofol has been used in patients at risk for cerebral ischemia (Ravussin and de Tribolet, 1993); however, no human outcome studies have been performed to determine its efficacy as a neuroprotectant. Results from studies on the anticonvulsant effects of propofol have been mixed; some data even suggest it has proconvulsant activity when combined with other drugs (Modica *et al.*, 1990). Thus, unlike thiopental, propofol is not a proven acute intervention for seizures.

**Cardiovascular.** Propofol produces a dose-dependent decrease in blood pressure that is significantly greater than that produced by thiopental (Grounds *et al.*, 1985; Langley and Heel 1988). The fall in blood pressure can be explained by both vasodilation and mild depression of myocardial contractility (Grounds *et al.*, 1985). Propofol appears to blunt the baroreceptor reflex or is directly vagotonic because smaller increases in heart rate are seen for any given drop in blood pressure after doses of propofol (Langley and Heel, 1988). As with thiopental, propofol should be used with caution in patients at risk for or intolerant of decreases in blood pressure.

**Respiratory and Other Side Effects.** At equipotent doses, propofol produces a slightly greater degree of respiratory

## Exhibit 16

# The history of barbiturates a century after their clinical introduction

Francisco López-Muñoz<sup>1</sup>  
 Ronaldo Ucha-Udabe<sup>2</sup>  
 Cecilio Alamo<sup>1</sup>

<sup>1</sup>Department of Pharmacology,  
 University of Alcalá, Madrid, Spain;

<sup>2</sup>WHO Fellow in Psychopharmacology  
 and Biological Psychiatry, National  
 University of Buenos Aires, Argentina

**Abstract:** The present work offers an analysis of the historical development of the discovery and use of barbiturates in the field of psychiatry and neurology, a century after their clinical introduction. Beginning with the synthesis of malonylurea by von Baeyer in 1864, and up to the decline of barbiturate therapy in the 1960s, it describes the discovery of the sedative properties of barbital, by von Mering and Fischer (1903), the subsequent synthesis of phenobarbital by this same group (1911), and the gradual clinical incorporation of different barbiturates (butobarbital, amobarbital, secobarbital, pentobarbital, thiopental, etc). We describe the role played in therapy by barbiturates throughout their history: their traditional use as sedative and hypnotic agents, their use with schizophrenic patients in so-called “sleep cures” (Klaesi, Cloetta), the discovery of the antiepileptic properties of phenobarbital (Hauptmann) and their use in the treatment of epilepsy, and the introduction of thiobarbiturates in intravenous anesthesia (Lundy, Waters). We also analyze, from the historical perspective, the problems of safety (phenomena of dependence and death by overdose) which, accompanied by the introduction of a range of psychoactive drugs in the 1950s, brought an end to barbiturate use, except in specific applications, such as the induction of anesthesia and the treatment of certain types of epileptic crisis.

**Keywords:** barbiturates, history of medicine, sedative-hypnotic drugs, “sleep cures”, epilepsy, anesthesia

## Introduction

Throughout the history of humanity, numerous therapeutic agents have been employed for their hypnotic and/or sedative properties, though the true effectiveness of many of them has been fairly limited (Alamo et al 1998). It suffices to mention alcohol itself (in different forms, such as hydromel or wine) or the alkaloids of opium and other narcotic plants (hemp, jimsonweed, belladonna, henbane, etc). More recently, around the late 19th and early 20th centuries, agents such as paraldehyde, chloral hydrate, and bromides were used, until the discovery, at the beginning of the 20th century, of the sedative and hypnotic properties of barbiturates, thanks to the prior synthesis of malonylurea by Adolf von Baeyer in 1864.

The clinical introduction of barbiturates begun a century ago (1904) when the Farbwerke Fr Bayer and Co brought onto the market the first agent of this type, diethyl-barbituric acid, giving rise to profound changes in the pharmacological approach to the psychiatric and neurological disorders of the time. A large number of previously untreatable patients gained access to treatment and improved their prognosis. The most significant results were obtained in the treatment of patients with serious neuroses and psychoses and with severe emotional repression, who as a result of being administered barbiturates, especially intravenously, overcame their inhibitions, thus facilitating psychotherapeutic treatment. Barbiturates were also useful in the treatment of sleep disorders as well as being the first truly effective

Correspondence: Francisco López-Muñoz  
 Department of Pharmacology, University  
 of Alcalá, C/ Juan Ignacio Luca de Tena 8,  
 28027 Madrid, Spain  
 Tel +34 91 724 8210  
 Fax +34 91 724 8205  
 Email frlopez@juste.net



pharmacological tools for the management of epileptic seizures. Furthermore, they opened up the field of intravenous anesthesia, playing a prominent role in anesthetic induction, above all for minor operations.

In the course of the 20th century, more than 2500 barbiturates were synthesized, 50 of which were eventually employed clinically. Their use was widespread and many still have some use today. One hundred years after the introduction in clinical pharmacology of the original compound, oxybarbiturates, in general, continue to be the selected drugs in the treatment of some serious forms of insomnia and in some types of epilepsy. Similarly, some thiobarbiturates and some ultrashort-acting barbiturates are still used today as inducers of general anesthesia. Nevertheless, currently, 5 or 6 derivatives of barbiturates are sufficient to cover the therapeutic applications that still require them.

## Sedative and anticonvulsant drugs in the pre-barbiturate era


Although, as mentioned, the therapeutic agents historically employed for their sedative, hypnotic, or anticonvulsant effects have been quite numerous, the most specific drugs in this regard have their origin in the 19th century. Such is the case of chloral hydrate, different alkaloids and, above all, bromides (Hollister 1983; Sneader 1985; Scott 1992; Lehmann 1993; Shorvon and Sander 1996; Shorter 1997; Alamo et al 1998; Healy 2002).

The second half of the 19th century is called by some authors, such as Shorter (1997), the “alkaloids era”. Alkaloids were introduced into psychiatry as sedatives and hypnotics, thanks to the isolation of morphine from opium, in 1805, by the German pharmacist Friedrich Sertürner. In 1861, Wilhelm Griesinger, in the second edition of his *Die Pathologie und Therapie der Psychischen Krankheiten*, defended the use of opium in sleep disorders, pointing out the improvements it brought about in patients suffering from anxiety. However, the alkaloids that met with most success were those isolated from different species of the *Solanaceae* family: plants known for their hallucinogenic effects, such as hyoscyamus, whose sedative and hypnotic properties were described by the Viennese pharmacologist Karl Schroff in 1868. In 1839, chemists at the E Merck company in Darmstadt (Germany) had already isolated hyoscyamine, another alkaloid, which became popular in the late 19th century, forming part of many of the “cocktails” administered in neuropsychiatric institutions at that time (Woodward 1994). Finally, the year 1880 saw the isolation

of hyoscyne (called scopolamine in North America), an alkaloid that was also widely used in psychiatric cocktails, such as the famous Hyoscyne Co A, which contained hyoscyne, morphine, and atropine, and was administered to highly excited and aggressive manic patients (Norton 1979).

The first drug that could truly be called hypnotic is chloral hydrate. Synthesized in 1832 by Justus von Liebig, a chemist from Giessen, it was not analyzed as a hypnotic until 1869 by the Berlin pharmacologist Oskar Liebreich. The hypothetical mechanism to which its action was ascribed was based on the mistaken belief that, in vivo, chloral hydrate was capable of transforming itself into formic acid and chloroform, whose properties were already known at that time (Sourkes 1992). Very soon, chloral hydrate substituted morphine and the *Solanaceae* alkaloids, given its convenience, as it could be administered without the need for injection, allowing treatment in the home and making it unnecessary to confine patients to neuropsychiatric institutions (Shorter 1997).

Nevertheless, it would be the bromides that were most widely used in the second half of the 19th century, either as sedatives or for the treatment of epilepsy, having been introduced for these applications by the internist and obstetrician Sir Charles Locock in 1857. It was in that year that Locock reported his results in the treatment with bromides in women with what the author has named as catamenial or hysteriform epileptic seizures, obtaining positive outcomes in 14 women out of a sample of 15. From that time on, bromides were widely introduced in asylums and similar institutions throughout Europe, given their sedative and antiepileptic properties, the relevant function in the latter case being to reduce the expression of the epileptic patients’ sexuality. Another contribution in relation to the neuropsychiatric use of bromides was made by the British doctor Neil MacLeod, who in 1897, while working in Shanghai, carried out the first “sleep cure” with these salts. MacLeod called it “the bromide sleep” (MacLeod 1900), and some authors, such as Shorter (1997), have considered this technique as the first pharmacological therapy that, within psychiatry, succeeded in improving the symptoms of psychiatric patients. However, the main problem with bromides resided in their high toxicity (neurological and gastrointestinal disorders, irritability, hallucinations, deliria, and lethargy), given their long half-life (elimination taking around 12 days) and their capacity for accumulation in tissue; as a result, they were gradually phased out after the introduction of barbiturates in the early part of the 20th century (Balme 1976).



**Figure 1** Synthesis of barbituric acid, from the combination of malonic acid (left) and urea (right).


Other substances used as hypnotics and sedatives and eventually as anticonvulsants were also introduced in the 19th century and the early decades of the 20th century. Such is the case of paraldehyde, discovered by Wildenbusch in 1829 and introduced into clinical practice by Vincenzo Cervello in 1882; and sulphonal, whose hypnotic action was discovered by chance by Eugen Baumann and Alfred Kast in 1887 (Kast 1888). Finally, those seeking to treat epilepsy turned, as well as to potassium bromide, chloral hydrate, or hyoscine, to a whole host of substances of more questionable efficacy, including opium, belladonna, atropine, stramonium, strophanthus, *cannabis indica*, and zinc oxide.

## The discovery and clinical introduction of barbiturates as sedative and hypnotic agents

Between the 1920s and the mid-1950s, practically the only drugs used as sedatives and hypnotics were barbiturates

(Lehmann and Ban 1970). From a chemical point of view, these drugs are closed-chain ureic compounds, whose nucleus is malonylurea (a combination of urea, a product present in animal excrement, and malonic acid, an acid derivative taken from apples) (Figure 1). Barbiturates were synthesized in 1864 by Adolf von Baeyer, though the synthetic process was developed and perfected by the French chemist Edouard Grimaux in 1879, making possible the subsequent widespread development of barbiturate derivatives (Carter 1951). Von Baeyer, a disciple of Robert W Bunsen and Friedrich A Kekulé, taught at the universities of Strasbourg and Munich, was the founder of what was to become the Bayer Chemical Co, and received the Nobel Prize in Chemistry in 1905 for his contribution to the development of organic chemistry (Figure 2a).

There are various hypotheses about the origin of the term “barbiturates” (Dundee and McIlroy 1982). According to one of these, Baeyer may have used this name for the compounds for sentimental reasons, in honor of his friend Barbara (Cohen 1943). Other authors, however, claim that the name derives from the fact that Baeyer celebrated his discovery in a tavern near his home that was frequented by artillery officers, who themselves were celebrating the day of their patron, St Barbara (Sharpless 1970). A third possibility is that the term is inspired by the “barbed” appearance of the crystals of these ureic compounds (Fieser 1944). In any case, it is clear that the union of the elements “barb(ara)” and “urea” forms the basis of the name.



**Figure 2** (a) Adolf von Baeyer (1835–1917); (b) Josef von Mering (1849–1908); (c) Emil Fischer (1852–1919).

## From malonylurea to barbital

The first of the barbiturates to come onto the market was diethyl-barbituric acid, also known as barbital, malonal, or gardenal. Synthesized in 1881 by Conrad and Guthzeit, on treating the argentic salt of barbituric acid with ethyl iodide, it was introduced clinically as a hypnotic by the German companies E Merck (Darmstadt) and F Bayer and Co (Elberfeld) in 1904, thanks to the work of Josef Freiherr von Mering (Figure 2b) and Emil Fischer (Nobel Prize in Chemistry, 1902) (Figure 2c).

Von Mering, who taught pharmacology at the University of Halle, had observed that some of the synthetic compounds obtained towards the end of the 19th century and commercialized as hypnotics, such as sulphonal, contained in their molecular structure a carbon atom with two ethyl groups. Furthermore, knowing of von Baeyer's work with derivatives of urea, von Mering decided to study the hypnotic properties of diethyl-acetylurea, and found that it was even more potent than sulphonal. The next step was to analyze the properties of 5,5-diethyl-barbituric acid, for which he turned to Fischer, an old friend from his student days. At that time, Fischer, doyen of the German organic chemists, was Professor of Chemistry at the University of Berlin. Moreover, Fischer was well acquainted with the chemistry of malonylurea, as he had been von Baeyer's assistant in Munich for eight years. Together with his nephew Alfred Dilthey, he tested the new, resynthesized product, demonstrating, in dogs, that its hypnotic power was far greater than that of von Mering's diethyl-acetylurea (Sneader 1985). When Fischer told his friend von Mering about this finding, the latter happened to be in the Italian city of Verona, and it was this that prompted him to call the new drug Veronal® (Cohen 1943; Sharpless 1970). Nevertheless, other authors argue that the name Veronal (from Latin, *verus*=true) was coined by Fischer, who claimed to have found the "true" hypnotic compound (Sneader 1985). This new hypnotic drug was patented by Fischer in January 1903, and two months later the first scientific data on barbiturates were published in a brief report (Fischer and von Mering 1903). The licence for its commercialization in the USA was granted to the Winthrop Chemical Company.

The term barbital for diethyl-barbituric acid is a later development, coming as a result of the economic effects of World War I. After the United States entered the conflict, in 1917, Congress passed the Trading with the Enemy Act 1917, which permitted them as a kind of war booty to manufacture German products protected by patent, modifying their generic name and with the profits going to

the American subsidiaries of the German companies (Sneader 1985). Thus, the American Medical Association approved the name barbital, whilst in the United Kingdom, through a similar mechanism, diethyl-barbituric acid came to be called barbitone. From this point on the two endings "-al" and "-one" could be found in the nomenclature of barbiturates.

Veronal had hypnotic, sedative, and anticonvulsant properties (Figure 3a). It could calm manic patients and help melancholic patients to sleep, and was an effective inducer of sleep in insomniacs. The first trials with barbital were carried out by Hermann von Husen (1904), a young psychiatrist affected by sleep disorders, who tried the new drug on himself. After taking 0.5 g of Veronal the first night and 1 g the following night, he reports:

In both cases, after 10–15 minutes, I fell into a growing state of dejection that led to deep sleep after around 30 minutes. After half a gram of Veronal I slept for 8 hours, and after a whole gram, around 9 hours. On the first morning I awoke fresh and rested; on the second morning, after the higher dose, I found it difficult to get out of bed (von Husen 1904, p 59).

## The consolidation of barbiturate therapy: phenobarbital

By means of small modifications to the chemical structure of the barbituric acid molecule, more than 2500 different agents were synthesized. The first barbital analogs, numbering around 18, were synthesized and tested by the group made up of von Mering, Fischer, and Dilthey. One of them, perhaps that most widely used subsequently, was phenobarbital, synthesized by Hörlein in 1911, on substituting one of the ethyl groups by a phenyl radical. Phenobarbital was employed in therapy as a hypnotic for the first time in 1912 by Loewe, Juliusburger, and Impens, and that same year it was commercialized by F Bayer and Co, under the name Luminal®. Phenobarbital, with a more prolonged pharmacological action than its predecessor, soon became "king of the barbiturates", both in hospitals and in outpatient care (Shorter 1997). This drug opened up the way, moreover, to another important therapeutic application of barbiturates, as will be mentioned later: the treatment of epilepsy.

Both Veronal (barbital) and Luminal (phenobarbital), the first two representatives of the series of barbiturates, were accepted by the international pharmacopoeia, such as the *United States Pharmacopoeia* (USP X) in 1926, and the *British Pharmacopoeia* in 1914 and 1932, respectively.


Later, both drugs were also included in the *Pharmacopoeia Internationalis*.

## Clinical introduction of the new barbiturates

The new barbiturates brought substantial advantages compared with their classical predecessors, such as a greater potency and duration of action, as well as a wider therapeutic range. However, of the several thousand that were synthesized, only about 50 came onto the market, and of these no more than a couple of dozen were regularly used in clinical practice. The next barbiturate to be used successfully in therapy was butobarbital, whose history begins in World War I. The British war effort required large quantities of acetone for the manufacture of explosives (Sneader 1985), and one of the solutions was provided by Chaim Weizmann, who would later become the first president of the state of Israel. Weizmann found that the bacteria *Clostridium acetobutylicum* was capable of transforming materials rich in starch into acetone and butyric alcohol, and at low industrial cost. After the war, the cost of butyric alcohol, a chemical that was as useful as it was expensive, fell drastically, thus permitting its use for obtaining numerous synthetic drugs. In 1920, Roger Adams

(Abbott Laboratories, Chicago, USA) synthesized the ester of 5-butyl-5-ethyl-malonic acid, an intermediate stage in the synthesis of a butyl analog of barbital, which was finally synthesized by Arthur Dox (Parke Davis and Company, Detroit, USA) in 1922, and marketed the following year by Abbott Laboratories, under the name Neonol® (Sneader 1985). Butobarbital (butethal in the USA) was three times as strong as barbital and its period of action was much shorter due to its lipophilicity, which greatly lowered the possibility of “rebound” drowsiness the day after administration.

In the years that followed, new barbiturates continued to come onto the market. In 1923, it was amobarbital (Amytal®), synthesized by Shonle and Moment (Eli Lilly Company, Indianapolis, USA) by adding a carbon atom to the butyl chain of butobarbital; and in 1929, Horace A Shonle also synthesized secobarbital (Seconal®). Both barbiturates had quite similar pharmacological properties to those of butobarbital (Sneader 1985). The next drugs of this series to be introduced were pentobarbital (Nembutal®), synthesized by Volwiler and Tabern (Abbott Laboratories) in 1930, and thiopental (Pentothal®). The latter, a sulfur derivative of pentobarbital, presented at the American Chemical Society congress in San Francisco in August 1935 (Tabern and Volwiler 1935), would revolutionize intravenous



**Figure 3** (a) Elixir Veronal from Dr Bustamante's Laboratories it is a "Practical treatment of insomnia". They have also added audaciously "Secure and harmless". Finally they say that "it tastes good and acts smoothly, being absorbed by the organism". (b) Advertisement for Abbott sodium pentobarbital in an American medical journal of 1933, highlighting its "short but powerful hypnotic effect and prolonged sedative action from small dosage".



**Table 1** Mean and maximum dosage of the pharmacological agents used as hypnotics before the benzodiazepine era

Drug	Dosage per administration		Daily maximum dosage
	Mean dosage	Maximum dosage	
Ethchlorvynol	250 mg	500 mg	750 mg
Chloral hydrate	500 mg	1000 mg	1000 mg
Paraldehyde	3 mL	8 mL	8 mL
Glutethimide	250 mg	500 mg	500 mg
Methypylon	200 mg	400 mg	400 mg
Methaqualone	200 mg	400 mg	600 mg
Phenobarbital	50–100 mg	200 mg	200 mg
Amobarbital	50–100 mg	200 mg	200 mg
Secobarbital	100 mg	200 mg	200 mg
Pentobarbital	100 mg	200 mg	200 mg
Sodium tripental	250 mg	500–1000 mg	–

NOTE: The doses indicated correspond only to the hypnotic use of these drugs. The maximum doses of the barbiturates are not considered when they are used as anticonvulsants.

anesthesia and would be the only representative of the thiobarbiturate family to be officially recognized, being accepted first by the *British Pharmacopoeia* (1942, 7th Add) and subsequently by the *United States Pharmacopoeia* (1947, USP XIII) and the *Pharmacopoeia Internationalis* (1951, Volume I). Figure 3b shows an advertisement for pentobarbital in an American journal of the time.

Table 1 shows the recommended dosages of barbiturates used as hypnotics together with those of other drugs also used as hypnotics prior to the clinical introduction of benzodiazepines at the end of the 1950s. Among these last agents, chemically different from barbiturates although with similar pharmacological actions, we have to mention glutethimide (USV Pharmaceutical Corporation, 1954), methypylon (Hoffmann-La Roche, 1955), methaqualone (King George Medical College, Lucknow, India, 1956; William H Rorer Inc, 1965), chlormethiazole (Hoffmann-La Roche, 1956), and ethchlorvynol (Pfizer, 1956). Most of these drugs were introduced as barbiturate substitutes, due to the fact that they seemed to offer a wider margin of safety. However, the clinical experience has demonstrated that their addiction liability and the severity of withdrawal symptoms were similar to those of barbiturates, and most of them were removed from the market some years later.

## The role of barbiturates in “sleep cures” for schizophrenic patients

The hypnotic properties of some barbiturates were rapidly applied to the treatment of psychotic patients, thanks to their induction of a state of deep and prolonged sleep. The pioneer

of these techniques was the Italian psychiatrist Giuseppe Epifanio, working at the University Psychiatric Clinic in Turin, who described his technique in an article published in 1915. The lack of impact of this development on the international scientific community can be attributed to the fact that it was published only in an Italian journal, and in the middle of the Great War (Epifanio 1915). It was on 25th March 1913 that Epifanio administered the first dose of Luminal to a girl aged 19 (FL) affected by manic-depressive psychosis, extending the treatment over a period of 4 days. The patient fell into a “deep sleep” that lasted until 9th April, was discharged at the end of June, and was in remission during the next two years. This case marked the beginning of what Manfred Bleuler would describe in 1955 as “the first of the great physical therapies” for mental disorders (Windholz and Witherspoon 1993).

However, the clinical introduction of these techniques is historically associated with Jakob Klaesi, a psychiatrist at the University Psychiatric Clinic in Zurich (Psychiatrische Universitätsklinik, Burghölzli, Switzerland). His “sleep cures” (“Dauerschlaf”, “Dauernarkose”), proposed in 1920 within the framework of the 59th Assembly of the Swiss Psychiatry Society (28th November 1920), enjoyed great prestige at the time and directly involved the use of barbiturates. Klaesi’s initial proposal was that his techniques for inducing deep hypnosis, taken from Epifanio, would facilitate communication between patient and psychotherapist (“to achieve a better relationship between doctor and patient”) (Shorter 1997, p 204). Klaesi introduced his method in Switzerland, and based it on pre-medication with morphine (0.01 mL) and scopolamine (0.001 mL) and the subsequent administration (intravenous or subcutaneous), over at least 6–7 days, of Somnifen® (Figure 4), a mixture of diethyl and dipropenyl-barbituric acid and diethylamine (2–4 mL), manufactured by the Hoffmann-LaRoche company. The percentage improvements reported by Klaesi, in samples of schizophrenic patients, ranged from 25% to 33%, which is 10% higher than the rates of spontaneous remission in this type of patient (Klaesi 1922). These cures (“prolonged sleep therapy”) acquired great popularity during the 1920s, with numerous variations as regards methodology and applications (agitated schizophrenic patients, delirium tremens, autism, morphine dehabituating, etc), though the administration of Somnifen was always involved (Windholz and Witherspoon 1993). Nevertheless, it is important to consider a fact mentioned in the first publication on the effectiveness of the method in schizophrenic patients: three of the 26 patients recruited died during the study due to



**Figure 4** The packaging of Somnifen®, produced by Hoffmann-LaRoche.

bronchopneumonia or hemorrhages in the cardiac muscles (Klaesi 1922). A few years later, some authors set the mortality rate with Somnifen at around 5% (Müller 1927).

The legacy of Somnifen was taken up at the same Swiss clinic in Burghölzli by pharmacologist Max Cloetta and psychiatrist Hans W Maier, who sought a compound that would be better tolerated. In 1934, they prepared a compound based on paraldehyde, amylene hydrate, chloral hydrate, alcohol, ephedrine hydrate, digalen, and isopropylallyl-barbituric acid, which they called Cloetta® or “Cloetta Mixture”, and which was rectally administered (Cloetta and Meier 1934). This preparation was widely used in schizophrenic patients, not only in the Zurich clinic (Boss, Monnier), but also elsewhere, such as in the Soviet Union by Ivan P Pavlov (Windholz and Witherspoon 1993). The most rigorous study with this mixture was carried out in Burghölzli by Marcel Monnier, who, with a sample of 125 schizophrenic patients, applied strict exclusion criteria (elderly patients and those with renal or respiratory disorders) before applying the preparation. Only 84 patients were given the Cloetta Mixture, and 53 of them improved (40 were even discharged from the hospital). Nevertheless, two patients died during the treatment as a result of respiratory complications associated with the medication (Monnier 1936).

Eliot Slater, of the Maudsley Hospital in London, recalled that “sleep cures” were “the only treatment we had back in the 1930s that was of any value in acute psychotic

disorders” (Slater 1975, p 74). After this initial period, the use of “sleep cures” based on barbiturates began to decline due in part to problems of safety, as well as to the clinical introduction of new biological therapies for the treatment of schizophrenic patients such as Sakel’s (1935) insulin shocks or the cardiazolic shocks of von Meduna (1937). Even so, as Shorter (1997) points out, “the story of barbituric narcosis has a corollary”. This refers to the work of D Ewen Cameron in the mid-1950s at the Psychiatry Department of the Allan Memorial Institute in Montreal (Canada). Financed by the Central Intelligence Agency (CIA), Cameron developed his technique of “psychic driving” (Cameron 1956), a prototype version of what would come to be known commonly as “brainwashing”. With this technique, in which barbiturates were also used, Cameron intended to take advantage of prolonged sleep to force his patients to listen to propaganda messages, which, in this case, were designed to quicken their recovery. In spite of its aims, eminently clinical, this work was widely criticized in the mass media at the time.

## Barbiturates as antiepileptic agents

With phenobarbital, in addition to confirmation of the excellent hypnotic effect of barbiturates, it was demonstrated that these drugs had significant anticonvulsant properties. The discovery of these properties took place in 1912, the year of their commercialization, and provided another example of serendipity in the field of psychopharmacology. Alfred Hauptmann, resident psychiatrist in Freiburg, was given responsibility for the care of epileptic inpatients. Finding it impossible to sleep properly because of the continual convulsive seizures of his patients, Hauptmann decided to administer them some of the new hypnotics on the market, among them phenobarbital. Surprisingly, Hauptmann observed that the incidence of seizures in patients treated with low doses of phenobarbital fell notably, not only during the night, but also during the day (Hauptmann 1912). One of Hauptmann’s most important conclusions was that phenobarbital not only reduced the number of seizures, but also their intensity, allowing many patients to leave the institutions and enjoy a normal working life.

It was in this way that the anticonvulsant properties of barbiturates were discovered, phenobarbital being the first truly effective drug for the treatment of epilepsy (Ivñez and Díez-Tejedor 1998). Table 2 shows, by way of example,

**Table 2** Anticonvulsant drugs used at the National Hospital (Queen Square) in London, before and after the clinical introduction of phenobarbital in the treatment of epilepsy

1910		1930	
Drugs of definite benefit	Drugs of doubtful benefit	Drugs of definite benefit	Drugs of doubtful benefit
Bromides	Monobromate of camphor	Bromides	Zinc salts
Chloral hydrate	Eosinate of sodium	Bromide combinations	Iron
Glycerophosphates	Chloretone	<b>Phenobarbital</b>	Digitalis
Borax	Antipyrin	Borax	Strophanthus
Belladonna		Double tartrate of borax and potassium	Calcium
Zinc salts		Belladonna	Opiates
Opium		Nitroglycerine	Hypnotics
Strychnine			
Chloride of calcium			
Atropine			

Adapted from Shorvon and Sander (1996).

the anticonvulsant agents commonly employed in the treatment of epilepsy before and after the introduction of phenobarbital.

However, the international acceptance of phenobarbital as an antiepileptic drug was seriously delayed, due first of all to the scarce significance outside Germany of the journal in which Hauptmann published the reports of his work (*Münchener Medizinische Wochenschrift*), and secondly, to the outbreak of World War I. Indeed, phenobarbitone was not commercialized in Great Britain until 1923, by the Winthrop Chemical Company. In one of his first reports on the use of phenobarbitone in England, Charles Brooks, Colony Medical Officer at the Chalfont Centre in London, noted its particular efficacy in severe cases of convulsions and in epileptic conditions with associated mental deficiency. Brooks also mentioned that if the barbiturate did not show a certain degree of effectiveness in the first months of treatment, the result of the therapy would not be satisfactory, so that it would be necessary to find an alternative (Brooks 1922). In a later report, Brooks made a close examination of patterns of use of phenobarbitone, concluding that it was more effective than bromides, but that it was not particularly useful in patients with low-intensity seizures (Brooks 1923).

It was precisely the Chalfont Centre that published, at the end of the 1920s, one of the first therapeutic guides for newly admitted epileptic patients, written by F Haward (Shorvon and Sander 1996). According to this guide, potassium bromide was the first-choice treatment, though it should be substituted by phenobarbital if there was no remission in the seizures within a given period of time (Table 2). If after three months of treatment the improvement was not clear, the guide recommended treatment with a combination of Luminal® and potassium bromide.

Moreover, it set down the recommended dosage for phenobarbitone: 1 grain (65 grams) in the morning and another at night for adult patients, and 1/2 grain in the case of children; the dose was to be increased gradually, according to the clinical response, but should never exceed 6 grains per day (Haward 1928). At the beginning of the 1930s, the use of phenobarbital superseded definitively that of bromides in the treatment of epileptic seizures, despite the first reports of pharmacological tolerance and the risk of seizures when withdrawal was too abrupt. Phenobarbital is currently the most widely-prescribed antiepileptic drug in the world (Shorvon 2000), even though in the developed countries it has passed onto a secondary plane in therapy, for the treatment of partial and generalized seizures, due to its profile of adverse effects.

In the years following the discovery of the antiepileptic properties of phenobarbital, there were studies of numerous barbiturate derivatives in the field of epilepsy, the most important being mephobarbital (Prominal®) (Weese 1932) and, above all, deoxybarbital or primidone (Mysoline®). Primidone was synthesized by Bogue and Carrington (Imperial Chemical Industries Ltd, ICI, Manchester, UK) in 1949, demonstrating its antiepileptic activity in patients with generalized seizures in 1952 (Handley and Stewart 1952). Initially, primidone awoke great therapeutic interest, as it was thought that its anticonvulsant effectiveness may be greater than that of other available barbiturates, and without sedative effects (Bogue and Carrington 1953), but this interest soon waned after it was demonstrated that phenobarbital was a metabolite of this drug, together with phenyl-ethyl-malonamide (Butler and Waddell 1956). Comparative clinical studies carried out with phenobarbital and its prodrug, primidone, showed no differences between

the two (Oleson and Dam 1967). Currently, primidone is still considered as being of some use in partial and secondary generalized seizures, but is not a first-choice drug. Unlike phenobarbital, it cannot be used in epileptic status, since no galenic formulation has been developed for its parenteral administration.

The discovery by Houston Merritt and Tracy Putnam (Boston City Hospital, USA) in 1938 of the anticonvulsant properties of phenytoin (the first drug to show that an antiepileptic need not be a hypnotic), in 1944 of trimethadione, and in the late 1950s of carbamazepine, extended the spectrum of antiepileptic drugs, resulting in decreased use of barbiturates in these applications.

## The use of barbiturates in intravenous anesthesia

Despite the existence of some publications on the use of Somnifen® as a general anesthetic as early as 1921 by the French anesthetist Daniel Bardet – who noted that his patients woke up very slowly and with serious headaches (Bardet 1921) – the first barbiturate to be used systematically in anesthesia was sodium sec-butyl-(2-bromo-allyl)-barbiturate (Pernocton®). This was introduced into the field by the German obstetrician Bumm in 1927 (Bumm 1927). Subsequently, as new barbiturates were synthesized for their oral administration as sedatives, sodium salts of the same drugs were formulated, which could be administered intravenously and used as anesthetics (Dundee and McIlroy 1982). Notable among the pioneers in this field is John S Lundy of the Mayo Clinic (Rochester, USA), who introduced sodium amobarbital (1929) and sodium pentobarbital (1930) in anesthesia.

The addition of a methyl group to the butobarbital molecule, by the chemists Kropp and Taub at Bayer (IG Farbenindustrie, Leverkusen) in the early 1930s, gave rise to hexobarbital, whose sodium salt (Evipal®), introduced into clinical anesthesia in 1932 (Weese and Scharpff 1932), constituted the first barbiturate agent that induced anesthesia. Ten years after its introduction, more than 10 million people had undergone operations with the help of this drug (Adams 1944). The duration of hexobarbital's action was shorter than that of its predecessors, given its greater lipophilicity, but under its effect some muscular movements occurred. This problem was solved through the next modification of the chemical structure of the basic nucleus of the barbiturates, the addition of a sulfur group to pentobarbital. Thus born were the agents that would revolutionize



**Figure 5** The packaging of Abbott Pentothal® at the time of its clinical introduction in the late 1930s. Pieces from the Museum of the Buenos Aires Anaesthesiology Association (Argentina).

intravenous anesthesia, the thiobarbiturates, thanks to the work of Volwiler and Tabern of Abbott Laboratories (Tabern and Volwiler 1935). These agents were studied as anesthetics at the Mayo Foundation (Rochester) by John Lundy's group, who gave the sulfur derivative of pentobarbital the name Thionembutal®. Its sodium salt was marketed as Pentothal (Figure 5). The team led by Ralph M Waters at the University of Wisconsin Medical School (Madison, USA) were the first to begin clinical administration of Pentothal, and published their results in 1936 (Pratt et al 1936). This agent rapidly displaced the rest of the barbiturates as an anesthetic, partly due to the swiftness of its onset and its short action period, and it currently remains the preferred intravenous anesthetic in many types of surgical intervention. Despite the anesthetic efficacy of both hexobarbital and thiopental, the barbiturates most commonly employed in surgery in the mid-20th century, they were not without their clinical problems. Such problems were brought to the public eye in particularly unfortunate fashion after the involvement of these agents, apparently due to malpractice, in numerous cases of death in patients treated in states of shock after the Japanese attack on Pearl Harbor in December 1941. Some authors went as far as describing these drugs as providing the "ideal form of euthanasia" (Halford 1943).

After World War II the search for anesthetic barbiturates continued, and new compounds such as thiobutobarbital (Horatz and Stürtzbecher 1952) were introduced, though the only one that truly challenged thiopental was methohexital (Brietal®), developed by SM Chernish's group at Lilly Research Laboratories (Indianapolis, USA) in 1956. In clinical trials, methohexital showed itself to be more potent than thiopental and to lead to quicker recovery in patients; it was recommended for use as an anesthetic



inducer in minor outpatient surgery (Taylor and Stoelting 1960). The subsequent development of other anesthetic agents for intravenous administration (hydroxydione, alphaxalone, etomidate, propofol, etc) led to a reduction in the use of barbiturates in this context.

## The peak and decline of barbiturate therapy

As mentioned earlier, chemists from different universities and pharmaceutical companies managed to synthesize over 2500 barbiturate derivatives. The differential pharmacokinetic properties of these agents made it possible to draw up a practical clinical classification, based on the duration of their pharmacological action (Hollister 1983). Thus, the barbiturates in the category of short or intermediate action (secobarbital, amobarbital, pentobarbital) were employed initially as hypnotics, whilst those of prolonged action (phenobarbital) were widely used as anxiolytics and anticonvulsants; ultrashort-acting agents, notably sodium thiopental, were especially useful as anesthetic inducers for minor operations (Table 3). From time to time, some barbiturates have been used in the treatment of other disorders. One such case is the use of primidone in the management of essential tremor (Koller et al 2000), while another is that of combinations of barbiturates and analgesics (salicylates, codeine, etc) in the treatment of headaches, migraines, and other types of pain (Wolf et al 1941), though such applications are considered counterproductive today.

Some barbiturates, such as sodium amytal and sodium pentothal (the latter being known as “the truth serum”) were widely known and used as coadjuvant agents for the exercise of narcoanalysis, as initially developed by Bleckwenn in 1930 (Bleckwenn 1930a, 1930b). In principle, the application of an infusion of barbiturates reverted temporarily the catatonic state of certain schizophrenic patients. These cures for catatonia allowed patients, for a few hours, to maintain conversations and interact with their environment, before returning to their state of lethargy. Despite the fact that the response was somewhat brief, these


cures were quite customary in European asylums in the 1930s and 1940s. But a variety of this technique became widespread during and after World War II: it consisted of the intravenous administration of a short-acting barbiturate, which had a disinhibiting effect (potentiating positive transfers) and facilitated the subsequent exercise of psychotherapy (a phenomenon referred to as “cathartic abreaction”) (Lehmann 1993). This technique was also called by other authors the “induced crepuscular method”.

It was during the 1930s and 1940s that barbiturates attained their greatest popularity and were most widely used, putting them in a position that could be compared, according to Hollister (1983), to that currently held by benzodiazepines. The barbiturates most commonly used at that time were phenobarbital, sodium amobarbital, sodium secobarbital, sodium pentobarbital, and sodium thiopental. Despite their widespread use during the first half of the 20th century, no barbiturate succeeded in eliminating the main drawbacks of these drugs, which were the phenomena of dependence and death by overdose (Johns 1977). Among the paradoxes of destiny is the possible death through overdose of the two scientists who introduced the first barbiturate, Fischer and von Mering, after some years of dependence upon these substances (Escotado 1996). To reduce these problems, from a legal perspective, a series of laws were passed aimed at regulating the distribution and sale of barbiturates. The first of these came into force in California in 1929. However, its effects were limited, if we consider, for example, that the production of barbiturates in the USA increased by more than 400% from 1933, with some 70 tons of these drugs sold in 1936. The problem continued during the following decade, and it became necessary to arrange special conferences for all those involved, such as that held in Washington, under the auspices of the American Pharmaceutical Association, on 12th October 1945 (*Conference on the Regulation of Use and Distribution of Barbiturates*). Barbiturate use in the pre-benzodiazepine period was such that, in the USA alone, production of these drugs reached, in 1955, the quantity

**Table 3** Classification and principal clinical applications of the barbiturates most commonly employed before World War II

	Barbiturates	Trade name	Chemical name	Clinical indications
Long-acting	Phenobarbital	Luminal	5-ethyl-5-phenylbarbituric acid	Sedative
Intermediate-acting	Amobarbital	Amytal	5-ethyl-5-isopentylbarbituric acid	Hypnotic
Short-acting	Pentobarbital	Nembutal	5-ethyl-5-(1-methylbutyl)-barbituric acid	Hypnotic and anticonvulsant
	Secobarbital	Seconal	5-allyl-5-(1-methylbutyl)-barbituric acid	Hypnotic
Ultrashort-acting	Thiopental	Pentothal	5-ethyl-5-(1-methylbutyl)-thiobarbituric acid	Anesthesia inducer

Adapted from Hollister (1983).




**Figure 6** Evolution of annual barbiturates production in USA for the period 1941–1960. Adapted from Fort (1964).

necessary for the treatment of 10 million people throughout an entire year. Figure 6 shows the industrial production of barbiturates and their derivatives in the USA during the 1940s and 1950s.

The capacity of barbiturates to cause dependence was described in the medical literature as early as one year after the commercialization of barbital (“the Veronal habit”), though reliable evidence of the potential of these drugs to generate abuse was not available until the 1950s (Glatt 1962). In fact, doses 4–6 times higher than the therapeutic dose as hypnotics of the short-acting barbiturates (400–600 mg/day of amobarbital, secobarbital, or pentobarbital)


brought about, if the treatment was sufficiently prolonged, authentic withdrawal syndromes when use was stopped. In order to palliate these effects, the Narcotics Expert Committee at the World Health Organization recommended (at their sessions of 7th–12th January, 1952, and 18th–24th October, 1956) that barbiturates should only be available on medical prescription. In spite of this, and according to different estimates, in 1965 there were 135 000 barbiturate addicts in England, whilst in the United States it was declared, by a special drug-dependence committee set up by President Kennedy in 1962, that there may be as many as 250 000 Americans addicted to barbiturates. Indeed, the USA currently produces 30 barbiturate pills per inhabitant per year (Escotado 1996). Some barbiturates (amobarbital and pentobarbital) have even found their way into mixtures with amphetamine derivatives (*goofballs*), such as Dexamy<sup>®</sup>, a combination of dextroamphetamine and amobarbital.

In relation to the frequent cases of death by overdose, given the small therapeutic margin of these substances, it should be pointed out that this was a common method in suicide attempts. It suffices to recall, in this regard, the famous case of Marilyn Monroe, on whose death certificate it clearly states “acute poisoning by overdose of barbiturates” (Figure 7). The lethal effect of these compounds was such that a mixture of barbiturates with other substances



**Figure 7** Death certificate of the actress Marilyn Monroe, issued on 28th August 1962. The circles indicate cause of death (“Acute barbiturate poisoning. Ingestion of overdose”) and the intentionality (“Probable suicide”).





**Figure 8** Deaths from overdose of barbiturates in England and Wales during the period 1905–1960 (Registrar-General's Statistical Review for England and Wales). Includes both accidental deaths and suicides. Adapted from Glatt (1962).

was even employed in some USA states for the execution of prisoners sentenced to death. Furthermore, there are classic reports of fatal overdose due to the “automatism phenomenon”, whereby the patient would take his or her dose, only to forget that he or she had already taken it, given the amnesic effect of the drug, and take it again, this process being repeated several times (Richards 1934). Figure 8 shows the evolution of number of deaths (accidental or suicide) by barbiturate overdose in England and Wales for the period 1905–1960. In this regard, and in the city of New York alone, in the period 1957–1963, there were 8469 cases of barbiturate overdose, with 1165 deaths (Sharpless 1970), whilst in the United Kingdom, between 1965 and 1970, there were 12 354 deaths attributed directly to barbiturates (Barracough 1974). These data should not surprise us, since in a period of just one year (1968), 24.7 million prescriptions for barbiturates were issued in the United Kingdom (Plant 1981). In view of these data, the Advisory Council Campaign in Britain took measures restricting the prescription of these drugs. Meanwhile, the prescription of prolonged-acting sedative barbiturates was strongly opposed through citizens' action campaigns such as CURB (Campaign on the Use and Restrictions of Barbiturates), especially active during the 1970s.

Furthermore, during the 1950s, when the use of barbiturates was at its peak, there took place a veritable revolution in the approach to psychiatric disorders, thanks to the introduction into clinical practice of the first pharmacological tools aimed specifically at treating these patients (Caldwell 1970; Jacobsen 1986; Ayd 1991; Lehmann 1993; Frankenburg 1994; López-Muñoz et al 2000; Ban 2001; Healy 2002). This “psychopharmacological revolution” began with the discovery and clinical use, from

1952, of chlorpromazine (López-Muñoz et al 2004), culminating in the commercialization of the first benzodiazepine, chlordiazepoxide, in 1960. The discovery of benzodiazepines was actually made possible, in part, by the 60 years of clinical and basic research provided by barbiturates, whose therapeutic life, from that time on, began to decline.

## Barbiturates today

Currently, the use of barbiturates is circumscribed to quite specific therapeutic applications (Charney et al 2001). Thus, phenobarbital and butabarbital are still used as sedatives in cases of gastrointestinal and asthmatic functional disorders, as well as to antagonize the adverse central stimulant effects of some drugs, such as ephedrine, dextroamphetamine, or theophylline. Phenobarbital is also used in cases of withdrawal syndromes of hypnosedative agents. In the field of neurology, barbiturates (phenobarbital and primidone) are still employed, not only in the treatment of certain types of epilepsy (partial and tonic-clonic generalized seizures), but also in the emergency treatment of some types of convulsions, such as those associated with tetanus, eclampsia, cerebral hemorrhage, status epilepticus, or different forms of poisoning. As intravenous anesthetic inducers, ultrashort-acting barbiturates are of use, mainly thiopental and methohexital, the latter also being administered rectally in children or as a sedative in some diagnostic imaging explorations. Table 4 shows the therapeutic applications of barbiturates that have survived to the present day.

In addition to these approved indications, the barbiturates present other current uses. Phenobarbital is capable of improving the hepatic transport of bilirubin in patients with hemolytic jaundice, so that it can be used in newborn babies to treat hyperbilirubinemia and kernicterus. At a diagnostic level, amobarbital, in low doses, can be injected directly into the carotid artery prior to neurosurgery to identify the dominant cerebral hemisphere. Finally, anesthetic doses of barbiturates can attenuate post-surgical cerebral edemas and have positive effects in cases of cardiac and cerebral ischemia, reducing the size of the infarcted region. Moreover, barbiturates have been used since the 1970s in the management of acute traumatic brain injury in their capacity to reduce intracranial pressure (Marshall et al 1979). The mechanism through which high-dose barbiturates appear to exert their intracranial pressure-lowering effects is double: reduction of metabolism (with the consequent lower oxygen demand by cerebral tissue)

**Table 4** Barbiturates currently employed and therapeutic applications

Barbiturate	Routes of administration	Therapeutic uses
Amobarbital	Oral, IM, IV	Insomnia Preoperative sedation Emergency management of seizures
Aprobarbital	Oral	Insomnia
Butobarbital	Oral	Insomnia Preoperative sedation
Mephobarbital	Oral	Epilepsy Daytime sedation
Methohexital	IV	Induction/maintenance of anesthesia
Pentobarbital	Oral, rectal, IM, IV	Insomnia Preoperative sedation Emergency management of seizures
Phenobarbital	Oral, IM, IV	Epilepsy Status epilepticus Daytime sedation
Primidone	Oral	Epilepsy
Secobarbital	Oral, rectal, IM, IV	Insomnia Preoperative sedation Emergency management of seizures
Thiopental	Rectal, IV	Induction/maintenance of anesthesia Preoperative sedation Emergency management of seizures

Adapted from Charney et al (2001).

**Abbreviations:** IM, intramuscular; IV, intravenous.

and modifications in vascular tone (Kassell et al 1980). Additionally some direct neuroprotective effects, such as membrane stabilization or inhibition of free radical-mediated lipid peroxidation, have been postulated (Piatt and Schiff 1984). Despite results of the multicenter randomized clinical trial published by Eisenberg et al (1988) that demonstrated the efficacy of high-dose barbiturates in severely head-injured patients with intractable intracranial pressure elevations, recent collaborations, based in Cochrane methodology, concluded that there is no evidence of health improvement in this type of patient (Roberts 2000).

The barbiturates introduced clinically one century ago were the first pharmacological agents to have demonstrated—in an historical period that was therapeutically inhospitable—a real efficacy in different neuropsychiatric disorders. They were the first-line treatment as hypnotics and anticonvulsants during the first half of the 20th century. The clinical results

obtained in the last years in other indications such as the treatment (acute or prophylactic) of traumatic brain injury, although contradictory, seems to confirm that, from the pharmacological perspective, the barbiturates continue furnishing certain novelties and that in their history the last page has not yet been written.

## References

- Adams RC. 1944. Intravenous anesthesia. New York: Hoeber.
- Alamo C, López-Muñoz F, Echániz T, et al. 1998. Fármacos ansiolíticos, sedantes e hipnóticos. In López-Muñoz F, Alamo C (eds). Historia de la Neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del Sistema Nervioso Central. Madrid: Ediciones Eurobook SL. p 245–68.
- Ayd FJ. 1991. The early history of modern psychopharmacology. *Neuropsychopharmacology*, 5:71–84.
- Balme R. 1976. Early medicinal uses of bromides. *J Royal Coll Physic*, 10:205–8.
- Ban TA. 2001. Pharmacotherapy of mental illness. A historical analysis. *Prog Neuro-Psychopharmacol Biol Psychiatr*, 25:709–27.
- Bardet D. 1921. Sur l'utilisation. Comme anesthésique général, d'un produit nouveau, le diéthyl-diallyl-barbiturate de diéthylamine. *Bull Gén Thérap Méd Chirurg Obstétr Pharm*, 172:27–33.
- Barracough BM. 1974. Are there safer hypnotics than barbiturates. *Lancet*, i:57–8.
- Bleckwenn WJ. 1930a. Narcosis as therapy in neuropsychiatric conditions. *JAMA*, 95:1168–71.
- Bleckwenn WJ. 1930b. Production of sleep and rest in psychotic cases. *Arch Neurol Psychiatry*, 24:365–75.
- Bogue JY, Carrington HC. 1953. The evaluation of mysoline – a new anticonvulsant drug. *Br J Pharmacol*, 8:230–5.
- Brooks C. 1922. Report of the Medical Officer. The National Society for Epileptics. Thirtieth Annual Report. p 19.
- Brooks C. 1923. Report of the Medical Officer. The National Society for Epileptics. Thirty-first Annual Report. p 23.
- Bumm R. 1927. Intavenose Narkosen mit Barbitur-saurederivaten. *Klin Wochenschr*, 6:725–6.
- Butler TC, Waddell WJ. 1956. Metabolic conversion of primidone (Mysoline) to phenobarbital. *Proc Soc Exp Biol NY*, 93:544–66.
- Caldwell AE. 1970. History of psychopharmacology. In Clark WG, Del Giudice J (eds). Principles of psychopharmacology. New York: Academic Pr. p 9–30.
- Cameron DE. 1956. Psychic driving. *Am J Psychiatry*, 112:502–9.
- Carter MK. 1951. The history of barbituric acid. *J Chem Educ*, 28:525–8.
- Cervello V. 1882. Sull' azione fisiologica della paraldeide e contributo allo studio del cloralio idrato. Ricerche. *Arch Soc Med*, 6:177–214.
- Charney DS, Mihic SJ, Harris RA. 2001. Hypnotics and sedatives. In Hardman JG, Limbird LE (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: MacGraw-Hill. p 399–427.
- Chernish SM, Gruber CM, Demeyer M, et al. 1956. Double blind comparison of compound 22451, pentothal and surital. *Fed Proc*, 15:409.
- Cloetta M, Maier AW. 1934. Über eine Verbesserung der psychiatrischen Dauernarkosebehandlung. *Zeitsch gesamte Neurol Psychiatrie*, 164:146–62.
- Cohen WAT. 1943. Chemisch-Historische Aanteekeningen. De nomenclatuur van enkele organische zuren. *Chemisch Weekblad*, 40:176.
- Conrad M, Guthzeit M. 1881. Über Barbitur-saurederivate. *Berichte*, 14:1943.



- Dundee JW, McIlroy PDA. 1982. The history of the barbiturates. *Anaesthesia*, 37:726–34.
- Eisenberg HM, Frankowski RF, Contant CF, et al. 1988. High-dose barbiturate control of elevated intracranial pressure in patient with severe head injury. *J Neurosurg*, 69:15–23.
- Epifanio G. 1915. L'ipnosi farmacologica prolungata e sua applicazione per la cura di alcune psicopatici. *Riv Patol Nerv Mentale*, 20: 273–308.
- Escototado A. 1996. Historia elemental de las drogas. Barcelona: Editorial Anagrama.
- Fieser LF. 1944. Organic chemistry. Boston: DC Heath and Company. p 247.
- Fischer E, von Mering J. 1903. Ueber ein neue Klasse von Schlafmitteln. *Therapie Gegenwart*, 44:97–101.
- Fort J. 1964. The problem of barbiturates in the United States of America. *UNDOC Bull Narc*, 1:17–35.
- Frankenburg FR. 1994. History of the development of antipsychotic medication. *Psychiatr Clin North Am*, 17:531–40.
- Glatt MM. 1962. The abuse of barbiturates in the United Kingdom. *UNODC Bull Narc*, 2:19–38.
- Griesinger W. 1861. Die Pathologie und Therapie der psychischen Krankheiten. 2nd ed. Stuttgart: Krabbe.
- Grimaux E. 1879. Synthèse des dérivés uriques de la série de l'alloxane. *Bull Soc Chim France*, 31:146.
- Halford FJ. 1943. A critique of intravenous anesthesia in war surgery. *Anesthesiology*, 4:24–30.
- Handley R, Stewart ASR. 1952. Mysoline: a new drug in the treatment of epilepsy. *Lancet*, 262:742.
- Hauptmann A. 1912. Luminal bei Epilepsie. *Münch Med Wochenschr*, 59:1907.
- Haward FC. 1928. Report of the Medical Officer. The National Society for Epileptics. Thirty-fifth Annual Report. p 24.
- Healy D. 2002. The creation of psychopharmacology. Cambridge: Harvard Univ Pr.
- Hollister LE. 1983. The pre-benzodiazepine era. *J Psychoactive Drugs*, 15:9–13.
- Horatz K, Stürtzbecher F. 1952. Neue Hilfsmittel in der Anaesthesie. *Anaesthesist*, 1:149–50.
- Impens E. 1912. Pharmakologisches über Luminal, oder Phenylethyl barbiturat-saure, ein neues Hypnoticum. *Dtsch Med Wochenschr*, 38:945–7.
- Ivñez V, Díez-Tejedor E. 1998. Fármacos antiepilepticos y anticonvulsivantes: aspectos históricos. In López-Muñoz, F, Alamo C (eds). Historia de la Neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del Sistema Nervioso Central. Madrid: Ediciones Eurobook SL. p 347–64.
- Jacobsen E. 1986. The early history of psychotherapeutic drugs. *Psychopharmacology*, 89:138–44.
- Johns MW. 1977. Self-poisoning with barbiturates in England and Wales during 1959–74. *BMJ*, i:1128–30.
- Juliusburger O. 1912. Ueber Luminal ein neues Hypnoticum und Sedativum. *Berl Klin Wochenschr*, 49:940–2.
- Kassell NF, Hitchon PW, Gerk MK, et al. 1980. Alterations in cerebral blood flow, oxygen metabolism, and electrical activity produced by high-dose thiopental. *Neurosurgery*, 7:598–603.
- Kast A. 1888. Sulfonal, ein Neues Schlafmittel. *Berl Klin Wochenschr*, 25:309–14.
- Klaesi J. 1922. Über die therapeutische Anwendung der “Dauernarkose” mittels Somnifens bei Schizophrenen. *Zeitsch gesamte Neurol Psychiatrie*, 74:557–92.
- Koller WC, Hristova A, Brin M. 2000. Pharmacological treatment of essential tremor. *Neurology*, 54(11 Suppl 4):30–8.
- Lehmann HE. 1993. Before they called it psychopharmacology. *Neuropsychopharmacology*, 8:291–303.
- Lehmann HE, Ban TA. 1970. Pharmacotherapy of tension and anxiety. Springfield: Charles C Thomas.
- Liebreich O. 1869. Das Chloralhydrat ein neues Hypnoticum und Anästheticum, und dessen Anwendung in die Medizin. Eine Arzneimittel-Untersuchung. Berlin: Muller.
- Locock C. 1857. Discussion of paper by EH Sieveking. Analysis of 52 cases of epilepsy observed by author. *Lancet*, i:527.
- Loewe S. 1912. Klinische Erfahrungen mit Luminal. *Dtsch Med Wochenschr*, 38:947–8.
- López-Muñoz F, Alamo C, Cuenca E. 2000. La “Década de Oro” de la Psicofarmacología (1950–1960): Trascendencia histórica de la introducción clínica de los psicofármacos clásicos. *Psiquiatria.COM* (electronic journal), Sep, 4 (3), URL: <http://www.psiquiatria.com/psiquiatria/revista/47/1800/?++interactivo>.
- López-Muñoz F, Alamo C, Rubio G, et al. 2004. Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology. *Prog Neuropsychopharmacol Biol Psychiatry*, 28:205–8.
- Lundy JS. 1929. A case illustrating the use of sodium iso-amylethyl barbiturate (sodium amytal). Report of the 48th Meeting of the Society of the Clinical Surgery. Apr 29–30.
- Lundy JS. 1930. Intravenous anesthesia: particularly hypnotic, anesthesia and toxic effects of certain new derivatives of barbituric acid. *Anesth Analg*, 9:210–17.
- Marshall LF, Smith RW, Shapiro HM. 1979. The outcome with aggressive treatment in severe head injuries: acute and chronic barbiturate administration in the management of head injury. *J Neurosurg*, 50: 26–30.
- McLeod N. 1900. The hormone sleep: a new departure in the treatment of acute mania. *BMJ*, i:134–6.
- Merritt HH, Putnam TJ. 1938. Sodium diphenylhydantoinate in treatment of convulsive disorders. *JAMA*, 111:1068–73.
- Monnier M. 1936. Die Dauerschlafbehandlung der Schizophrenen mit Narkosenmischung von Cloetta an der Psychiatrischen Klinik Burghölzli – Zürich. *Nervenarzt*, 9:14–29.
- Müller M. 1927. Die Dauernarkose mit flüssigem Dial bei Psychosen, speziell bei manisch-depressivem Irresein. *Zeitsch gesamte Neurol Psychiatrie*, 107:522–43.
- Norton A. 1979. Depression. *BMJ*, 2:429–30.
- Oleson OV, Dam M. 1967. The metabolic conversion of primidone to phenobarbitone in patients under long-term treatment. *Acta Neurol Scand*, 43:348–56.
- Piatt JH, Schiff SJ. 1984. High dose barbiturate therapy in neurosurgery and intensive care. *Neurosurgery*, 15:427–44.
- Plant M. 1981. What aetiologies? In Edwards G, Busch C (eds). Drug problems in Britain. A review of ten years. London: Academic Pr. p 245–80.
- Pratt TW, Tatum AL, Hathaway HR, et al. 1936. Sodium ethyl (1-methyl butyl) thiobarbiturate: preliminary experimental and clinical study. *Am J Surg*, 31:464–6.
- Richards R. 1934. Symptoms of poisoning by hypnotics of barbituric acid groups. *BMJ*, i:331.
- Roberts I. 2000. Barbiturates for acute traumatic brain injury. *Cochrane Database Syst Rev*, 2:CD000033.
- Sakel M. 1935. Neue Behandlung der Schizophrenie. Vienna: Perles.
- Scott DF. 1992. The discovery of antiepileptic drugs. *J Hist Neurosci*, 1:111–18.
- Sharpless SK. 1970. The barbiturates. In Goodman LS, Gilman A (eds). The pharmacological basis of therapeutics. 4th ed. New York: The MacMillan Company. p 98–120.
- Shonle HA, Moment A. 1923. Some new hypnotics of the barbituric acid series. *J Am Chem Soc*, 45:243–9.
- Shorter E. 1997. A history of psychiatry. From the era of the asylum to the age of Prozac. New York: J Wiley.

- Shorvon SD. 2000. Handbook of epilepsy treatment. Oxford: Blackwell Science.
- Shorvon SD, Sander JWAS. 1996. Historical introduction. The treatment of epilepsy at the National Hospital; Queen Square, 1857-1939: a mirror of the first phase of the modern history of medical and surgical therapy. In Shorvon SD, Dreifuss F, Fish D, et al (eds). The treatment of epilepsy. Oxford: Blackwell Science. p xvii–xliv.
- Slater E. 1975. Psychiatry in the thirties. *Contemp Rev*, 226:70–5.
- Sneader W. 1985. Drug discovery: the evolution of modern medicines. Chichester: J Wiley.
- Sourkes TL. 1992. Early clinical neurochemistry of CNS-active drugs. Chloral hydrate. *Mol Chem Neurophath*, 17:21–30.
- Tabern DL, Volwiler EH. 1935. Sulfur-contained barbiturate hypnotics. *J Am Chem Soc*, 57:1961–3.
- Taylor C, Stoelting VK. 1960. Methohexital sodium—a new ultrashort acting barbiturate. *Anesthesiology*, 21:29–34.
- Volwiler EH, Tabern DL. 1930. 5,5-substituted barbituric acid. *J Am Chem Soc*, 52:393–407.
- Von Baeyer A. 1864. Untersuchungen über die Harnsauregruppe. *Annalen*, 130:129.
- Von Husen H. 1904. Über Veronal. *PNW*, 6:57–61.
- Von Meduna L. 1937. Die Konvulsionstherapie der Schizophrenie. Halle: Marhold.
- Weese H. 1932. Pharmakologie des Prominal. *Dtsch Med Wochenschr*, 58:696.
- Weese H, Scharpff W. 1932. Evipan, ein neuartiges Einschlafmittel. *Dtsch Med Wochenschr*, 58:1205–7.
- Windholz G, Witherspoon LH. 1993. Sleep as cure for schizophrenia: a historical episode. *Hist Psychiatry*, 4:83–93.
- Wolf HG, Hardy JD, Goodell H. 1941. Measurement of the effect of the pain threshold of acetylsalicylic acid, acetanilid, acetophenetidin, aminopyrine, ethyl alcohol, trichlorethylene, a barbiturate, quinine, ergotamine, tartrate and caffeine, and analysis of their relation to the pain experience. *J Clin Invest*, 20:63–80.
- Woodward SB. 1994. Observations on the medical treatment of insanity (1846). *Am J Psychiatry*, 151(Suppl 6):220–30.

## Exhibit 17



# PHYSICIANS' DESK REFERENCE®

**Senior Vice President, Directory Services:** Paul Walsh

**Vice President, Sales and Marketing:** Dikran N. Barsamian

**National Sales Manager, Custom Sales:** Anthony Sorce

**Senior Account Manager:** Frank Karkowsky

**Account Managers:**

Marion Gray, RPh

Lawrence C. Keary

Suzanne E. Yarrow, RN

**National Sales Manager, Medical Economics Trade Sales:**

Bill Gaffney

**Senior Business Manager:** Mark S. Ritchin

**Financial Analyst:** Wayne M. Soltis

**Vice President, Clinical Communications and**

**New Business Development:** Mukesh Mehta, RPh

**New Business Development Manager:** Jeffrey D. Dubin

**Manager, Drug Information Services:** Thomas Fleming, RPh

**Drug Information Specialists:** Maria Deutsch, MS, PharmD, CDE;

Christine Wyble, PharmD

**Editor, Directory Services:** David W. Sifton

**Project Manager:** Edward P. Connor

**Senior Associate Editor:** Lori Murray

**Assistant Editor:** Gwynned L. Kelly

**Director of Direct Marketing:** Michael Bennett

**Direct Mail Manager:** Lorraine M. Loening

**Senior Marketing Analyst:** Dina A. Maeder

**Director of Production:** Carrie Williams

**Data Manager:** Jeffrey D. Schaefer

**Production Manager:** Amy Brooks

**Production Coordinators:** Gianna Caradonna, Dee Ann DeRuvo,

Melissa Katz

**Index Supervisor:** Johanna M. Mazur

**Index Editor:** Shannon Reilly

**Art Associate:** Joan K. Akerlind

**Digital Imaging Supervisor:** Shawn W. Cahill

**Digital Imaging Coordinator:** Frank J. McElroy, III

**Pharmaceutical Coordinator:** Mary Kaadan

**Electronic Publishing Designer:** Livio Udina

**Fulfillment Managers:** Louis J. Bolcik, Stephanie DeNardi

## MEDICAL ECONOMICS

### THOMSON HEALTHCARE

Copyright © 2001 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, Pocket PDR®, The PDR® Family Guide to Prescription Drugs®, The PDR® Family Guide to Women's Health and Prescription Drugs®, and The PDR® Family Guide to Nutrition and Health® are registered trademarks used herein under license. PDR for Ophthalmic Medicines™, PDR for Nonprescription Drugs and Dietary Supplements™, PDR Companion Guide™, PDR Pharmacopoeia™ Pocket Edition, PDR® for Herbal Medicines™, PDR for Nutritional Supplements™, PDR® Medical Dictionary™, PDR® Nurse's Drug Handbook™, PDR® Nurse's Dictionary™, The PDR® Family Guide Encyclopedia of Medical Care™, The PDR® Family Guide to Natural Medicines and Healing Therapies™, The PDR® Family Guide to Common Ailments™, The PDR® Family Guide to Over-the-Counter Drugs™, and PDR® Electronic Library™ are trademarks used herein under license.

**Officers of Medical Economics Company:** President and Chief Executive Officer: Curtis B. Allen; Vice President, New Media: L. Suzanne BeDell; Vice President, Corporate Human Resources: Pamela M. Bilash; Chief Financial Officer: Christopher Caridi; Vice President and Controller: Barry Gray; Vice President, Finance: Donna Santaripa; Senior Vice President, Directory Services: Paul Walsh; Senior Vice President, Operations: John R. Ware

ISBN: 1-56363-330-2



Albumin (Human) 25%.....	806
Bebutin VH Immuno.....	807
Burninate 5% Solution, USP.....	807
Burninate 25% Solution, USP.....	807
Felba VH Immuno.....	810
Gammagard S/D.....	812
Hemofil M.....	814
Iveqgam EN IGIV.....	816
Proplex T.....	818
Recombine.....	820

**BAXTER PHARMACEUTICAL PRODUCTS INC.** 821  
95 Spring Street  
New Providence, NJ 07974

Direct Inquiries to:  
Professional Services Department  
(800) ANA-DRUG  
(800) 262-3784

For Medical Emergencies Contact:  
Kent Allenby  
VP Clinical Research & Medical Affairs  
(800) ANA-DRUG  
(800) 262-3784

Sales and Ordering:  
To place an order call or fax:  
(800) 667-0959  
FAX: (877) 702-3580

Products Described:	
Alfentanil HCl Injection.....	821
Ativan Injection.....	821
Atmucurium Besylate Injection.....	821
Atropine Sulfate Injection, USP.....	822
Brevibloc Injection.....	822
Bumetanide Injection, USP.....	824
Butorphanol Tartrate Injection, USP.....	824
Cisplatin Injection.....	824
Diazepam Injection, USP.....	825
Diltiazem Hydrochloride Injection.....	825
Dobutamine Hydrochloride Injection.....	825
Doxorubicin Hydrochloride for Injection, USP.....	825
Duramorph Injection.....	825
Enlon Injection.....	825
Enlon-Plus Injection.....	826
Ethane Liquid for Inhalation.....	826
Etropside Injection.....	826
Fentanyl Citrate Injection, USP.....	826
Fluorouracil Injection, USP.....	826
Forane Liquid for Inhalation.....	826
Furosemide Injection, USP.....	827
6% Hetastarch in 0.9% Sodium Chloride Injection.....	827
Ketorolac Tromethamine Injection, USP.....	827
Labetalol Hydrochloride Injection, USP.....	828
Lidocaine HCl Injection, USP.....	828
Meperidine Hydrochloride Injection, USP - Dosette.....	828
Meperidine Hydrochloride Injection, USP - Tubex.....	828
Methoxyrinate Injection, USP.....	828
Metoprolol Injection, USP.....	829
Midazolam HCl Injection.....	829
Morphine Sulfate Injection, USP - Dosette.....	830
Morphine Sulfate Injection, USP - Tubex.....	830
Naloxone HCl Injection, USP.....	830
Neostigmine Methylsulfate Injection, USP.....	830
Pancuronium Bromide Injection.....	830
Phenylephrine Hydrochloride Injection, USP.....	830
Propofol Injectable Emulsion 1%.....	831
Revox Injection.....	831
Robinul Injectable.....	831
Sodium Nitroprusside Injection.....	831
Sufentanil Citrate Injection, USP.....	831
Suprane Liquid for Inhalation.....	832
Thiopental Sodium for Injection, USP.....	835
Vecuronium Bromide for Injection.....	835

**BAYER CORPORATION PHARMACEUTICAL DIVISION** 307, 342, 836  
400 Morgan Lane  
West Haven, CT 06516

For Medical Information Contact:  
Director, Clinical Services  
(800) 288-8371  
(203) 812-2000

Adverse Drug Experiences:  
(888) 765-3203

Products Described:	
Adalat Capsules.....	307, 836
Adalat CC Tablets.....	307, 837
Avelox Tablets.....	342, 839
Baycol Tablets.....	307, 843
Biluride Tablets.....	307, 848
Cipro I.V. Pharmacy Bulk Package.....	307, 856
Cipro Oral Suspension.....	307, 847
Cipro Tablets.....	307, 847
DTIC-Dome.....	860
Mithracin for Intravenous Use.....	861
Mylex-G 500 mg Vaginal Tablets.....	863
Nimotop Capsules.....	308, 863
Onic Domeboro Solution.....	308, 865
Procede Tablets.....	308, 865
Transyl Injection.....	868

**BAYER CORPORATION PHARMACEUTICAL DIVISION BIOLOGICAL PRODUCTS** 308, 871  
400 Morgan Lane  
West Haven, CT 06516

For Medical Information Contact:  
Director, Clinical Services  
(800) 468-0894  
(203) 812-2000

Adverse Drug Experiences:  
(888) 765-3203

Products Described:	
BayGam.....	871
BayHop B.....	872
BayRab.....	874
BayRho-D Full Dose.....	876
BayRho-D Mini-Dose.....	876
BayTel.....	878
Camimune N, 5% Solvent/Detergent Treated.....	308, 879
Camimune N, 10% Solvent/Detergent Treated.....	308, 882
Kofite-DV1.....	885
Kofite-HP.....	887
Kogenate.....	888
Kogenate FS.....	890
Konyne 80.....	892
Plasbumin-5.....	893
Plasbumin-20.....	894
Plasbumin-25.....	895
Plasmanate.....	896
Proslatin.....	897
Thrombate III.....	898

**BEACH PHARMACEUTICALS** 308, 900  
Division of Beach Products, Inc.  
5220 S. Manhattan Avenue  
Tampa, FL 33611

Direct Inquiries to:  
Richard Stephen Jenkins  
(813) 839-6565  
FAX: (813) 837-2511

Manufacturing and Distribution:  
201 Delaware Street  
Greenville, SC 29605  
(800) 845-8210

Products Described:	
Beech Tablets.....	308, 900
K-Phos M.F. Tablets.....	308, 900
K-Phos Neutral Tablets.....	308, 900
K-Phos No. 2 Tablets.....	308, 900
K-Phos Original (Sodium Free) Tablets.....	308, 901
Uroqid-Acid No. 2 Tablets.....	308, 901

**BEDFORD LABORATORIES** 902  
A Division of Ben Venue Laboratories, Inc.  
300 Northfield Road  
Bedford, OH 44146

Direct Inquiries to:  
Customer Service  
(800) 562-4797  
FAX: (440) 232-6264

For Medical Emergencies Contact:  
Professional Services  
(800) 521-5169

Products Described:	
Censibid for Injection.....	902
Glucagen for Injection Diagnostic Kit.....	903

Other Products Available:	
Acetazolamide for Injection USP	
Acetylcysteine Solution, USP (not for injection)	
Acyclovir for Injection USP	
Alprostadil Injection, USP	
Amikacin Sulfate Injection, USP	
Atmucurium Besylate Injection	
Azathioprine Sodium for Injection, USP	
Bumetanide Injection, USP	
Butorphanol Tartrate Injection, USP CIV	
Caffeine and Sodium Benzoate Injection USP	
Chloroprocaine Hydrochloride Injection, USP	
Cladribine Injection	
Colchicine Injection, USP	
Cyclosporine Injection, USP	
Cytarabine for Injection USP	
Doxorubicin Hydrochloride Injection (Solution)	
Desmopressin Acetate Injection	
Dihiazem Hydrochloride Injection	
Dipyridamole Injection	
Dobutamine Injection USP	
Doxorubicin Hydrochloride for Injection, USP	
Doxorubicin Hydrochloride Injection, USP	
Enalaprilat Injection	
Ephedrine Sulfate Injection, USP	
Ergonate Maleate	
Etomidate Injection	
Etropside Injection	
Floxuridine for Injection USP	
Fluphenazine Decanoate Injection	
Folic Acid Injection, USP	

**BERLEX LABORATORIES** 308, 905  
300 Fairfield Road  
Wayne, NJ 07470

Direct Inquiries to:  
(973) 694-4100

For Medical Information and to Report Drug Adverse Events Contact:  
Department of Epidemiology and Medical Affairs  
300 Fairfield Road  
Wayne, NJ 07470  
(888) BERLEX-4

Products Described:	
Beaspace Tablets.....	308, 905
Beaspace AP Tablets.....	308, 908
Climate Transdermal System.....	308, 912
Levlen 21 Tablets.....	308, 916
Levlen 28 Tablets.....	308, 916
Levlin 21 Tablets.....	308, 916
Levlin 28 Tablets.....	308, 916
Quinaglut Dura-Tabs Tablets.....	308, 924
Tri-Levlen 21 Tablets.....	308, 916
Tri-Levlen 28 Tablets.....	308, 916

**BERLEX LABORATORIES** 308, 927  
15049 San Pablo Avenue  
P.O. Box 4099  
Richmond, CA 94804-0099

Direct Inquiries to:  
(888) BERLEX-4

Products Described:	
Beasuron for SC Injection.....	308, 927
Fludars for Injection.....	308, 931

**BERNA PRODUCTS, CORP.** 308, 933  
4216 Ponce de Leon Boulevard  
Coral Gables, FL 33146

Direct Inquiries to:  
Myrna Entralgo  
(305) 443-2900, Ext. 221  
(800) 533-5899

For Medical Information Contact:  
Generally:  
Andres Murai, Jr.  
(305) 443-2900  
(800) 533-5899  
In Emergencies:  
Andres Murai, Jr.  
(305) 443-2900  
(800) 533-5899

Products Described:	
Vivotif Berna.....	308, 933

**BERTEK PHARMACEUTICALS INC.** 308, 935  
781 Chestnut Road  
Morgantown, WV 26505

For Medical Information Contact:  
Clinical Affairs Department  
3711 Collins Ferry Road  
Morgantown, WV 26504  
(888) 823-7835  
FAX: (304) 285-6453

Products Described:	
Acticin Cream.....	308, 935
Avita Cream.....	308, 935
Avita Gel.....	308, 937
Clorpres Tablets.....	308, 938
Digitek Tablets.....	840
Granulex Aerosol.....	943
Kristalose for Oral Solution.....	943
Maxzide Tablets.....	308, 943
Maxzide-25 mg Tablets.....	308, 943
Mentax Cream.....	308, 945
Sulfamylon Cream.....	847
Sulfamylon Topical Solution.....	947
Zegam Tablets.....	308, 948

Other Products Available:  
Biothane Temporary Burn Dressing  
Flexderm Hydrogel Wound Dressing  
Flexzan Wound Dressing  
Hydrocol Hydrocolloid Wound Dressing  
Serban Wound Dressing

**BEUTLICH LP PHARMACEUTICALS** 952  
1541 Shields Drive  
Waukegan, IL 60085-8304

FAX: (847) 473-1122  
Email: info@beutlich.com  
Website: http://www.beutlich.com

Products Described:	
Ceo-Two Evacuant Suppository.....	952
Hurricane Topical Anesthetic Aerosol Spray, 2 oz. Wild Cherry.....	952
Hurricane Topical Anesthetic Gel: 1 oz. Wild Cherry, Fresh Mint, Pina Colada, Watermelon, 1/6 oz. Wild Cherry, Watermelon.....	952
Hurricane Topical Anesthetic Liquid: 1 oz. Wild Cherry and Pina Colada, 25 ml Dry Handle Swab Wild Cherry, 1/6 oz. Wild Cherry.....	952
Hurricane Topical Anesthetic Spray Extension Tubes (200).....	952
Hurricane Topical Anesthetic Spray Kit.....	952
Peridin-C Tablets.....	952

**BIOGEN, INC.** 952  
14 Cambridge Center  
Cambridge, MA 02142

Direct Inquiries to:  
Customer Service  
(800) 456-2255  
FAX: (617) 679-3100

For Medical Emergencies Contact:  
Customer Service  
(800) 456-2255  
FAX: (617) 679-3100

Products Described:	
Avonex.....	952

**BIOGLAN PHARMA, INC.** 956  
7 Great Valley Parkway  
Suite 301  
Malvern, PA 19355

Direct Inquiries to:  
(610) 232-2000  
FAX: (610) 232-2020

Products Described:	
Micanol 1% Cream.....	956
Therapyin Z Topical Solution.....	956
Zonalon Cream.....	956

**BIO-TECHNOLOGY GENERAL CORP.** 310, 1075  
BTG Pharmaceuticals  
70 Wood Avenue South  
Iselin, N.J. 08830

Direct Inquiries to:  
(732) 632-8800

For Medical Information or Emergencies Contact:  
(800) 741-2698

For Customer Service and Ordering:  
(800) 741-2698  
FAX: (800) 741-2696

Products Described:	
Delatestryl Injection.....	310, 1075
Oxandrin Tablets.....	310, 1076

**BLAINE PHARMACEUTICALS** 956  
1515 Production Drive  
Burlington, KY 41005

For Inquiries or Medical Information Contact:  
(859) 283-9437  
(800) 633-9353  
FAX: (859) 283-9460  
E-mail: blainepharma.com

Products Described:	
Mag-Ox 400 Tablets.....	956
Uro-Mag Capsules.....	956

**BLANSETT PHARMACAL CO., INC.** 956  
P.O. Box 638  
North Little Rock, AR 72115

Direct Inquiries to:  
Customer Service  
(501) 758-8635  
FAX: (501) 758-5369

Products Described:	
Anolox 300 Capsules.....	956
Cortane-B Aqueous Ear Drops.....	956
Cortane-B Otic Drops.....	956
Nalex-A Liquid.....	956
Nalex-A Tablets.....	956

Other Products Available:  
Cortane-B Otic Lotion  
Nalex Expectorant  
Prolex DH Liquid  
Prolex DM Liquid  
Prolex-D Tablets  
Relagard



## INFORMATION

BAXTER PHARMACEUTICAL/835

**ADVERSELY RELATED:** Incidence less than 1% in more patients, regardless of severity. Reactions reported only from experience or in the literature, not seen in considered rare and are italicized.

Arrhythmia, bigeminy, abnormal electrocardiogram, myocardial ischemia, vasodilation, Hepatitis, Agitation, dizziness, Asthma, dyspnea, hypoxia.

**CAUSE UNKNOWN:** Incidence less than 1% in 3 or more patients, regardless of severity.

Fever, Hemorrhage, myocardial infarct, Increased creatinine phosphokinase, Myalgia, Pruritis.

**CAUTIONS** for information regarding pediatric use: Infant hyperthermia.

**CAUTIONS:** Transient elevations in glucose and blood pressure may occur as with use of other anesthetics.

## USE AND DEPENDENCE

Abuse liability, and dependence associated with SUPRANE® (desflurane, USP) have not been

## CAUTION

Overdosage, or suspected overdosage, take appropriate discontinuous administration of SUPRANE® (desflurane, USP), maintain a patent airway, institute controlled ventilation with oxygen, and ensure cardiovascular function.

## ADMINISTRATION

DESFLURANE (desflurane, USP) from a vaporizer designed and designated for use with desflurane.

System of general anesthesia must be individualized to the patient's response (see INDIVIDUAL DOSE). The following two tables provide dosage based upon age and drug interaction. ASA physical status I or II patients.

## DOSE ON MAC OF DESFLURANE

MEAN ± SD (percent atmospheres)

N	O <sub>2</sub> 100%	N	N <sub>2</sub> O 60%
5	9.2 ± 0.0	-	-
5	9.4 ± 0.4	-	-
4	10.0 ± 0.7	5	7.5 ± 0.6
3	9.1 ± 0.6	-	-
-	-	5	6.4 ± 0.4
4	8.6 ± 0.6	-	-
5	8.1 ± 0.6	-	-
4	7.3 ± 0.0	4	4.0 ± 0.3
4	6.0 ± 0.3	6	2.8 ± 0.6
6	6.2 ± 0.6	6	1.7 ± 0.4

Crossover pairs (using up-and-downs method) (percent)

Midazolam decreases the amounts of SUPRANE® (desflurane, USP) required to produce anesthesia. Data is based on studies of drug interaction.

## DESFLURANE, USP, MAC WITH FENTANYL OR MIDAZOLAM

MEAN ± SD (percent reduction)

	18-30 years	31-65 years
Desflurane	6.4 ± 0.0	6.3 ± 0.4
Fentanyl	3.5 ± 1.9 (46%)	3.1 ± 0.6 (15%)
Midazolam	3.0 ± 1.2 (53%)	2.3 ± 1.0 (64%)
Desflurane	6.9 ± 0.1	6.9 ± 0.6
Fentanyl	-	4.9 ± 0.9 (16%)
Midazolam	-	4.9 ± 0.5 (17%)

Desflurane, USP) decreases the doses of neuromuscular agents required (see PRECAUTIONS, Drug Interactions).

Incidence of anesthesia with in-flow rates of 1.5 L/min, the alveolar concentration of desflurane within 10% of the inspired concentration.

## THIOPENTAL SODIUM

Cat/Kit Number  
Syringe Kits<sup>1</sup>  
2580-0101  
Injection Kits<sup>2</sup>  
2530-0101  
2540-0101  
2550-0101

Thiopental Sodium  
for Injection, USP

500 mg  
1 g  
2.5 g  
5 g

Diluent  
Volume

20 mL  
40 mL  
100 mL  
200 mL

Reconstituted  
Concentration (%)

2.5  
2.5  
2.5  
2.5

NDC Number

10019-258-95  
10019-253-99  
10019-252-97  
10019-255-98

<sup>1</sup> Syringe Kits contain 1 vial of Thiopental Sodium for Injection, USP, 1 vial of 0.9% Sodium Chloride Injection, USP, 1 sterile syringe and needle.

<sup>2</sup> Injection Kits contain 1 vial of Thiopental Sodium for Injection, USP, 1 vial of Sterile Water for Injection, USP, sterile transfer spikes.

## SAFETY AND HANDLING

**Occupational Caution:** There is no specific work exposure limit established for SUPRANE® (desflurane, USP). However, the National Institute for Occupational Safety and Health Administration has recommended an 8-hr, time-weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N<sub>2</sub>O).

The predicted effects of acute overexposure by inhalation of SUPRANE® (desflurane, USP) include headache, dizziness or (in extreme cases) unconsciousness.

There are no documented adverse effects of chronic exposure to halogenated anesthetic vapors (Waste Anesthetic Gases or WAGs) in the workplace. Although results of some epidemiological studies suggest a link between exposure to halogenated anesthetics and increased health problems (particularly spontaneous abortion), the relationship is not conclusive. Since exposure to WAGs is one possible factor in the findings for these studies, operating room personnel, and pregnant women in particular, should minimize exposure. Precautions include adequate general ventilation in the operating room, the use of a well-designed and well-maintained scavenging system, work practices to minimize leaks and spills while the anesthetic agent is in use, and routine equipment maintenance to minimize leaks.

## STORAGE

Store at room temperature, 15°-30°C (59°-86°F). SUPRANE® (desflurane, USP) has been demonstrated to be stable for the period defined by the expiration dating on the label.

Rx only

BAXTER

Mfd. and Mktd. by affiliates of  
Baxter Healthcare Corporation  
Deerfield, IL 60015 USA

Revised: June 1998

For Product Inquiry 1 800 ANA DRUG  
400-447-05

## THIOPENTAL SODIUM

[thi-o-pen-tal so-die-um]


For Injection, USP

## DESCRIPTION

Thiopental Sodium for Injection, USP is a thiobarbiturate, the sulfur analogue of sodium pentobarbital.

The drug is prepared as a sterile lyophilized powder and, after reconstitution with an appropriate diluent, is administered by the intravenous route.

Thiopental Sodium, USP is chemically designated sodium 5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate and has the following structural formula:



The drug is a yellowish, hygroscopic powder, stabilized with anhydrous sodium carbonate as a buffer (60 mg/kg of Thiopental Sodium).

## HOW SUPPLIED

Thiopental Sodium for Injection, USP, (Lyophilized) is available as follows:

[See table above]

Syringe Kits and Injection Kits are individually packaged. Store product prior to reconstitution at controlled room temperature 15°-30°C (59°-86°F).

Store reconstituted solution in a cool place and use within 24 hours of mixing. Administer only clear solution.


## VECURONIUM BROMIDE

For Injection

Rx only

## DESCRIPTION

Vecuronium Bromide for Injection is a nondepolarizing neuromuscular blocking agent of intermediate duration, chemically designated as piperidinium, 1-[(2β, 3α, 5α, 16β, 17β)-3, 17-bis(acetyloxy)-3-(1-piperidinyl)androstan-16-yl]-1-methyl-, bromide. The structural formula is:



Its molecular formula is C<sub>34</sub>H<sub>57</sub>BrN<sub>2</sub>O<sub>4</sub> with molecular weight 637.74.

Vecuronium Bromide for Injection is supplied as a sterile nonpyrogenic freeze-dried buffered cake of very fine microscopic crystalline particles for intravenous injection only. Each 10 mL vial contains:

Vecuronium Bromide 10 mg, Citric Acid Anhydrous 20.75 mg, Sodium Phosphate Dibasic Anhydrous 16.25 mg, Mannitol (to adjust tonicity) 97 mg, pH is adjusted with sodium hydroxide and/or phosphoric acid if necessary, pH: 3.5-4.5. Each 20 mL vial contains: Vecuronium Bromide 20 mg, Citric Acid Anhydrous 41.5 mg, Sodium Phosphate Dibasic Anhydrous 32.5 mg, Mannitol (to adjust tonicity) 194 mg, pH is adjusted with sodium hydroxide and/or phosphoric acid if necessary, pH: 3.5-4.5. When reconstituted with Bacteriostatic Water for Injection, USP, CONTAINS 0.9% w/v BENZYL ALCOHOL WHICH IS NOT FOR USE IN NEWBORNS.

## HOW SUPPLIED

Vecuronium Bromide for Injection is supplied as follows:

NDC Number	Packaging Configuration	Vial Size
10019-481-01	Vecuronium Bromide for Injection 10 mg (diluent not supplied) Shelf pack carton of 10 individual vials.	10 mL
10019-482-02	Vecuronium Bromide for Injection 20 mg (diluent not supplied) Shelf pack carton of 10 individual vials.	20 mL

Store at controlled room temperature 15°-30°C (59°-86°F). PROTECT FROM LIGHT.

## EDUCATIONAL MATERIAL

## Educational Resources

Baxter Pharmaceutical Products Inc offers a wide range of educational materials free of charge to physicians, nurse-anesthetists, post-anesthesia nurses and hospital pharmacists. They are available from Baxter PPI sales representatives or by writing to: Baxter Pharmaceutical Products Inc, 95 Spring Street, New Providence, NJ 07974, or by calling (800) 262-3764.



considered rare and are italicized.  
Arrhythmia, bigeminy,  
abnormal electrocardiogram,  
myocardial ischemia,  
vasodilation,  
Hepatitis,  
Agitation, dizziness,  
Asthma, dyspnea, hypoxia.

ONSHIP UNKNOWN: Incidence less than  
1 in 3 or more patients, regardless of  
3)

3) Fever,  
Hemorrhage, myocardial  
infarct.  
Nutrition: Increased creatinine  
phosphokinase.  
System: Myalgia.  
Signs: Pruritis.

IONS for information regarding pediatric  
ant hyperthermia.  
Signs: Transient elevations in glucose and  
count may occur as with use of other anes-

AND DEPENDENCE  
Drug abuse liability, and dependence associ-  
PRANE® (desflurane, USP) have not been

IF  
f overdosage, or suspected overdosage, take  
actions: discontinue administration of SU-  
flurane, USP, maintain a patent airway, in-  
crease controlled ventilation with oxygen, and  
pulse cardiovascular function.

D ADMINISTRATION  
LANE® (desflurane, USP) from a vaporizer  
signed and designated for use with desflu-

ration of general anesthesia must be individu-  
on the patient's response (see INDIVIDUAL  
DOSE). The following two tables provide  
a potency based upon age and drug interaction  
dominately ASA physical status I or II pa-

TOF AGE ON MAC OF MAC OF DESFLURANE  
MEAN ± SD (percent atmospheres)

N	O <sub>2</sub> 100%	N	N <sub>2</sub> O 60%
6	9.2 ± 0.0	-	-
5	9.4 ± 0.4	-	-
4	10.0 ± 0.7	5	7.5 ± 0.8
3	9.1 ± 0.6	-	-
-	-	5	6.4 ± 0.4
4	8.6 ± 0.6	-	-
5	8.1 ± 0.6	-	-
4	7.3 ± 0.0	4	4.0 ± 0.3
4	6.0 ± 0.3	6	2.8 ± 0.6
6	6.2 ± 0.6	6	1.7 ± 0.4

of crossover pairs (using up-and-down method  
response)

benzodiazepines decrease the amounts of SU-  
(desflurane, USP) required to produce anesthesia.  
ing table is based on studies of drug interaction  
action.

OF (desflurane, USP) MAC WITH FENTANYL  
OR MIDAZOLAM  
MEAN ± SD (percent reduction)

	18-30 years	31-65 years
Fentanyl	6.4 ± 0.0 3.5 ± 1.9 (46%)	6.3 ± 0.4 3.1 ± 0.6 (51%)
Midazolam	3.0 ± 1.2 (53%)	2.3 ± 1.0 (64%)
Desflurane	6.9 ± 0.1	5.9 ± 0.6 4.9 ± 0.9 (16%)
Isopropyl	-	4.9 ± 0.5 (17%)

DO (desflurane, USP) decreases the doses of neu-  
blocking agents required (see PRECAUTIONS,  
actions).  
Maintenance of anesthesia with inflow rates of  
more, the alveolar concentration of desflurane  
be within 10% of the inspired concentration.  
Figure 1 in Pharmacokinetics section.)

FLUORIDE  
DO (desflurane, USP), NDC 10019-641-24, is pack-  
in color-coded bottles containing 240 mL desflu-

Kits<sup>2</sup>  
2550-0101  
2550-0101  
2550-0101  
0 g  
100 mL  
200 mL  
2.6  
2.6  
10019-255-99  
10019-255-97  
10019-255-96

- 1 Syringe Kits contain 1 vial of Thiopental Sodium for Injection, USP; 1 vial of 0.9% Sodium Chloride Injection, USP; 1 sterile syringe and needle.
- 2 Injection Kits contain 1 vial of Thiopental Sodium for Injection, USP; 1 vial of Sterile Water for Injection, USP; sterile transfer spikes.

## SAFETY AND HANDLING

**Occupational Caution:** There is no specific work exposure limit established for SUPRANE® (desflurane, USP). However, the National Institute for Occupational Safety and Health Administration has recommended an 8-hr, time-weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N<sub>2</sub>O).

The predicted effects of acute overexposure by inhalation of SUPRANE® (desflurane, USP) include headache, dizziness or (in extreme cases) unconsciousness.

There are no documented adverse effects of chronic exposure to halogenated anesthetic vapors (Waste Anesthetic Gases or WAGs) in the workplace. Although results of some epidemiological studies suggest a link between exposure to halogenated anesthetics and increased health problems (particularly spontaneous abortion), the relationship is not conclusive. Since exposure to WAGs is one possible factor in the findings for these studies, operating room personnel, and pregnant women in particular, should minimize exposure. Precautions include adequate general ventilation in the operating room, the use of a well-designated and well-maintained scavenging system, work practices to minimize leaks and spills while the anesthetic agent is in use, and routine equipment maintenance to minimize leaks.

## STORAGE

Store at room temperature, 15°-30°C (59°-86°F). SUPRANE® (desflurane, USP) has been demonstrated to be stable for the period defined by the expiration dating on the label.

## Rx only

## BAXTER

Mfd. and Mkt'd. by affiliates of  
Baxter Healthcare Corporation  
Deerfield, IL 60015 USA  
Revised: June 1995  
For Product Inquiry 1 800 ANA DRUG  
400-447-05

## THIOPENTAL SODIUM


[thi-ō-pent-āl sō-dē-ūm]

For Injection, USP

## DESCRIPTION

Thiopental Sodium for Injection, USP is a thiobarbiturate, the sulfur analogue of sodium pentobarbital. The drug is prepared as a sterile lyophilized powder and, after reconstitution with an appropriate diluent, is administered by the intravenous route.

Thiopental Sodium, USP is chemically designated sodium 5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate and has the following structural formula:



The drug is a yellowish, hygroscopic powder, stabilized with anhydrous sodium carbonate as a buffer (60 mg/g of Thiopental Sodium).

## HOW SUPPLIED

Thiopental Sodium for Injection, USP, (Lyophilized) is available as follows:  
[See table above]  
Syringe Kits and Injection Kits are individually packaged. Store product prior to reconstitution at controlled room temperature 15°-30°C (59°-86°F). Store reconstituted solution in a cool place and use within 24 hours of mixing. Administer only clear solution.

## VECURONIUM BROMIDE


for Injection

Rx only

THIS DRUG SHOULD BE ADMINISTERED BY ADE-  
QUATELY TRAINED INDIVIDUALS FAMILIAR  
WITH ITS ACTIONS, CHARACTERISTICS, AND HAZ-  
ARDS.

## DESCRIPTION

Vecuronium Bromide for Injection is a nondepolarizing neuromuscular blocking agent of intermediate duration, chemically designated as piperidinium, 1-[(2S, 3a, 5a, 16S, 17B)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, bromide. The structural formula is:



Its molecular formula is C<sub>24</sub>H<sub>47</sub>BrN<sub>2</sub>O<sub>4</sub> with molecular weight 637.74.

Vecuronium Bromide for Injection is supplied as a sterile nonpyrogenic freeze-dried buffered cake of very fine microscopic crystalline particles for intravenous injection only. Each 10 mL vial contains: Vecuronium Bromide 10 mg; Citric Acid Anhydrous 20.75 mg; Sodium Phosphate Dibasic Anhydrous 16.25 mg; Mannitol (to adjust tonicity) 97 mg. pH is adjusted with sodium hydroxide and/or phosphoric acid if necessary. pH: 3.5-4.5. Each 20 mL vial contains: Vecuronium Bromide 20 mg; Citric Acid Anhydrous 41.5 mg; Sodium Phosphate Dibasic Anhydrous 32.5 mg; Mannitol (to adjust tonicity) 194 mg. pH is adjusted with sodium hydroxide and/or phosphoric acid if necessary. pH: 3.5-4.5. When reconstituted with Bacteriostatic Water for Injection, USP, CONTAINS 0.9% w/v BENZYL ALCOHOL WHICH IS NOT FOR USE IN NEWBORNS.

## HOW SUPPLIED

Vecuronium Bromide for Injection is supplied as follows:

NDC Number	Packaging Configuration	Vial Size
10019-481-01	Vecuronium Bromide for Injection 10 mg (diluent not supplied) Shelf pack carton of 10 individual vials.	10 mL
10019-482-02	Vecuronium Bromide for Injection 20 mg (diluent not supplied) Shelf pack carton of 10 individual vials.	20 mL

Store at controlled room temperature 15°-30°C (59°-86°F).  
PROTECT FROM LIGHT.

## EDUCATIONAL MATERIAL

### Educational Resources

Baxter Pharmaceutical Products Inc offers a wide range of educational materials free of charge to physicians, nurse anesthetists, post-anesthesia nurses and hospital pharmacists. They are available from Baxter PPI sales representatives or by writing to: Baxter Pharmaceutical Products Inc, 96 Spring Street, New Providence, NJ 07974, or by calling (800) 262-3784.

For information on over-the-counter drugs,  
consult PDR For Nonprescription Drugs.

## Exhibit 18



# **Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only**

---

## **Guidance for Industry and Food and Drug Administration Staff**

**Document issued on: November 25, 2013**

**The draft of this document was issued on June 1, 2011.**

**For questions regarding this document contact Elizabeth Mansfield, by phone at (301) 796-4664, or by email at [elizabeth.mansfield@fda.hhs.gov](mailto:elizabeth.mansfield@fda.hhs.gov). For questions relating to devices regulated by CBER, contact the Office of Communications, Outreach and Development, CBER at 301-827-1800 or 800-835-4709.**



**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health  
Office of In Vitro Diagnostic Device Evaluation and Safety**



**Center for Biologics Evaluation and Research**

*Contains Non-binding Recommendations*

## Preface

### Public Comment

You may submit written comments and suggestions at any time for Agency consideration to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, (HFA-305), Rockville, MD, 20852. Submit electronic comments to <http://www.regulations.gov>. Identify all comments with the docket number 2011-D-0305. Comments may not be acted upon by the Agency until the document is next revised or updated.

### Additional Copies

Additional copies are available from the Internet at:  
[http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm\[insert specific number\].htm](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm[insert specific number].htm) or <http://www.fda.gov/cber/guidelines.htm>. You may also send an e-mail request to [dsmica@fda.hhs.gov](mailto:dsmica@fda.hhs.gov) to receive an electronic copy of the guidance or send a fax request to 301-847-8149 to receive a hard copy. Please use the document number 1723 to identify the guidance you are requesting.

Or, contact:

Office of Communication, Outreach and Development, HFM-40

Center for Biologics Evaluation and Research

Food and Drug Administration

1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448

Internet:

<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm>

Tel: 800-835-4709 or 301-827-1800

E-mail: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov)

*Contains Non-binding Recommendations*

## Table of Contents

<b>I. INTRODUCTION.....</b>	<b>4</b>
<b>II. REGULATORY REQUIREMENTS FOR RESEARCH USE ONLY AND INVESTIGATIONAL USE ONLY IVD PRODUCTS.....</b>	<b>5</b>
<b>III. RESEARCH USE ONLY AND INVESTIGATIONAL USE ONLY <i>IN VITRO</i> DIAGNOSTIC PRODUCTS .....</b>	<b>7</b>
<b>A. RESEARCH USE ONLY IN VITRO DIAGNOSTIC PRODUCTS.....</b>	<b>7</b>
<b>B. INVESTIGATIONAL USE ONLY IN VITRO DIAGNOSTIC PRODUCTS .....</b>	<b>7</b>
<b>IV. APPROPRIATE LABELING AND DISTRIBUTION PRACTICES FOR RUO AND IUO PRODUCTS .....</b>	<b>8</b>
<b>A. LABELING OF RUO AND IUO IVD PRODUCTS.....</b>	<b>8</b>
1. Research Use Only Labeling .....	8
2. Investigational Use Only Labeling .....	8
<b>B. DISTRIBUTION PRACTICES THAT ARE INCONSISTENT WITH RUO/IUO DESIGNATIONS.....</b>	<b>9</b>
1. Instructions for use for an IVD product labeled RUO or IUO .....	10
2. Validation and verification of clinical diagnostic testing using IVD products labeled RUO or IUO .....	10
<b>C. OTHER RELEVANT PRACTICES.....</b>	<b>11</b>
1. Use of a “certification program” .....	11
2. Software labeled RUO or IUO .....	11
<b>V. FDA’S COMPLIANCE APPROACH.....</b>	<b>11</b>

*Contains Non-binding Recommendations*

# **Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only**

---

## **Guidance for Industry and Food and Drug Administration Staff**

---

*This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.*

### **I. Introduction**

FDA is issuing this guidance document to provide the current thinking of the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER) on when in vitro diagnostic (IVD) products<sup>1</sup> are properly labeled “for research use only” (RUO) or “for investigational use only” (IUO)<sup>2</sup>. FDA is concerned that the distribution of unapproved and uncleared IVD products labeled RUO or IUO, but intended for purposes other than research or investigation (for example, for clinical diagnostic use<sup>3</sup>), has led, in some cases, to the clinical diagnostic use of products with unproven performance characteristics, and with manufacturing controls that are

---

<sup>1</sup> “In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body. These products are devices as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the act), and may also be biological products subject to section 351 of the Public Health Service Act.” Title 21, Code of Federal Regulations (CFR), section 809.3(a).

<sup>2</sup> This guidance is only intended to apply to IVD products that have not been approved, cleared or licensed for any use, and it is not intended to address off-label uses of any approved, cleared or licensed products.

<sup>3</sup> Throughout this guidance document, references to “clinical diagnostic use” and “use in clinical diagnosis” include use in making medical treatment decisions.



*Contains Non-binding Recommendations*

inadequate to ensure consistent manufacturing of the finished product. Use of such tests for clinical diagnostic purposes may mislead healthcare providers and cause serious adverse health consequences to patients, who are not aware that they are being diagnosed with or treated based on the results of tests with research or investigational products. FDA is issuing this guidance to clarify the requirements applicable to RUO and IUO IVD products, including that RUO and IUO labeling must be consistent with the manufacturer's intended use of the device.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

## **II. Regulatory Requirements for Research Use Only and Investigational Use Only IVD products**

Section 520(g) of the FD&C Act, 21 U.S.C. 360j(g), provides for the exemption of devices intended for investigational use from certain requirements of the Act if such devices comply with the procedures and conditions prescribed by that section and by regulation. For example, devices intended for investigational use that meet applicable requirements may be exempted from premarket notification and premarket approval requirements of sections 510, 515, 520(g)(2)(A) of the Act (21 U.S.C. 360, 360e, 21 U.S.C. 360j(g)(2)(A)); *see also* 21 CFR 812.1(a). A product's intended use refers to the "objective intent" of those responsible for labeling the product.<sup>4</sup> Intent is determined by such persons' expressions or may be shown by the circumstances surrounding the distribution of the article.<sup>5</sup>

### **Device Investigations Subject to IDE Regulation**

FDA's investigational device exemption (IDE) regulation is found at 21 CFR part 812. Under 21 CFR 812.5, investigational devices must bear a label that states the following: "CAUTION--Investigational device. Limited by Federal (or United States) law to investigational use." The labeling may not represent that the device is safe or effective for the purposes for which it is being investigated. 21 CFR 812.5(b). The IDE regulation also prohibits certain conduct by sponsors and investigators pertaining to the investigation and distribution of investigational devices, among other practices. See 21 CFR 812.7.

### **Device Investigations Exempt from IDE Regulation**

Investigations of diagnostic devices that meet the criteria at section 812.2(c)(3) are exempt from the regulations at 21 CFR 812, with the exception of section 812.119. The criteria at section 812.2(c)(3) include specifying that testing:

---

<sup>4</sup> See, 21 CFR 801.4

<sup>5</sup> See, *id.*

*Contains Non-binding Recommendations*

- be non-invasive,
- not require an invasive sampling procedure that presents a significant risk,
- not by design or intention introduce energy into a subject, and
- not be used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.

The criteria in section 812.2(c)(3) also include compliance with labeling requirements section CFR 809.10(c), which exempts shipments and other deliveries of IVDs from certain labeling requirements if either (1) the device complies with part 812, or (2) the investigation is not subject to part 812 and one of the following conditions is met:

- (i) For a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product, all labeling bears the statement, prominently placed: "For Research Use Only. Not for use in diagnostic procedures."
- (ii) For a product being shipped or delivered for product testing prior to full commercial marketing (for example, for use on specimens derived from humans to compare the usefulness of the product with other products or procedures which are in current use or recognized as useful), all labeling bears the statement, prominently placed: "For Investigational Use Only. The performance characteristics of this product have not been established."

For purposes of this guidance document, "labeled RUO" refers to IVD products labeled in accordance with section 809.10(c)(2)(i); "labeled IUO" refers to IVD products labeled in accordance with section 809.10(c)(2)(ii) unless otherwise specified. Examples of products that meet the criteria for these designations are provided in Section III.

Because these products are exempt from most regulatory controls, it is important that they are not distributed for clinical diagnostic uses.

Mere placement of an RUO or IUO label on an IVD product does not render the device exempt from otherwise applicable clearance, approval, or other requirements. FDA may determine that the device is intended for use in clinical diagnosis based on other evidence, including how the device is marketed.

In general, if evidence shows that an IVD product is inappropriately labeled RUO or IUO, and that the product does not qualify for an investigational device exemption under 520(g) of the Act, and is not cleared, approved, or 510(k)-exempt, the device would be misbranded under sections 502(a) and 502(o) of the Act, 21 U.S.C. 352(a), 352(o), and adulterated under section 501(f) of the Act, 21 U.S.C. 351(f).

*Contains Non-binding Recommendations*

### **III. Research Use Only and Investigational Use Only In Vitro Diagnostic Products**

Both RUO and IUO products are IVD products currently under development and not approved for clinical diagnostic use. Because they are being shipped for investigations pertaining to product development and not clinical use, these products are exempt from most regulatory controls including IDE regulation. The term RUO refers to devices that are in the laboratory phase of development. The term IUO refers to devices that are in the product testing phase of development.

#### **A. Research Use Only In Vitro Diagnostic Products**

An RUO product is an IVD product that is in the laboratory research phase of development and is being shipped or delivered for an investigation that is not subject to part 812. During the research phase of development, the focus of manufacturer-initiated studies is typically to evaluate design, limited-scale performance, and issues such as usability of the test. Some examples of products FDA would consider to be in this research phase include:

- Tests that are in development to identify test kit methodology, necessary components, and analytes to be measured.
- Instrumentation, software, or other electrical/mechanical components under development to determine correct settings, subcomponents, subassemblies, basic operational characteristics, and possible use methods.
- Reagents under development to determine production methods, purification levels, packaging needs, shelf life, storage conditions, etc.

FDA also recognizes that there are certain products, such as instruments, systems, and reagents that are labeled for research use only and intended for use in the conduct of non-clinical laboratory research with goals other than the development of a commercial IVD product, i.e., these products are used to carry out research and are not themselves the object of the research. These include products intended for use in discovering and developing medical knowledge related to human disease and conditions. For example, instruments and reagents intended for use in research attempting to isolate a gene linked with a particular disease may be labeled for research use only when such instruments and reagents are not intended to produce results for clinical use.

#### **B. Investigational Use Only In Vitro Diagnostic Products**

An IUO product is an IVD product that is being shipped or delivered for product testing that is not subject to 21 CFR part 812 (with the exception of §812.119, Disqualification of clinical investigator) prior to full commercial marketing (for example, for testing of specimens derived from humans to compare the usefulness of the product with other products or procedures which are in current use or recognized as useful). Examples of IVD products under investigation that FDA considers to fall in this category include those that are being

*Contains Non-binding Recommendations*

evaluated in comparison studies that use archived or fresh specimens to determine performance characteristics.

## **IV. Appropriate Labeling and Distribution Practices for RUO and IUO Products**

### **A. Labeling of RUO and IUO IVD Products**

#### **1. Research Use Only Labeling**

With respect to IVD products that are appropriately labeled RUO, the RUO labeling is meant to serve as a warning, to prevent such products from being used in clinical diagnosis, patient management, or an investigation that is not exempt from 21 CFR part 812. In general, IVD products that are intended for clinical diagnosis or patient management must be labeled “For *In vitro* diagnostic use”<sup>6</sup> and be in compliance with all relevant regulations for *In vitro* diagnostic devices.

An IVD product should not be labeled RUO if it is intended for use in a clinical investigation subject to 21 CFR part 812 or for clinical diagnostic use outside an investigation (for example, in clinical diagnosis for standard medical practice). FDA would consider such an IVD product to be misbranded under section 502(a) of the Act, 21 U.S.C. 352(a), if it were labeled “For Research Use Only” or otherwise labeled solely for research use, because such labeling would be false or misleading.

#### **2. Investigational Use Only Labeling**

Similarly, with respect to IVD products that are appropriately labeled IUO, the IUO labeling is meant to serve as a warning that products so labeled should not be used in clinical diagnosis, patient management, or an investigation that is not exempt from 21 CFR part 812.

An IVD product should not be labeled IUO if it is intended for non-investigational purposes, such as in clinical diagnostic use outside of an investigation. FDA would consider such an IVD product to be misbranded under section 502(a) of the Act, 21 U.S.C. 352(a), if it was labeled with the statement: “For Investigational Use Only” or “Investigational device.”<sup>7</sup>

<sup>6</sup> 21 CFR 809.10(a)(4). Alternatively, some IVD products may be appropriately labeled as analyte specific reagents (see 21 CFR 864.4020 and 21 CFR 809.10(e)(1)(x) or (xi), or as general purpose reagents (see 21 CFR 864.4010 and 21 CFR 809.10(d)(1)(iv)).

<sup>7</sup> IVD products intended for investigational use in a manner that is not consistent with an exempted investigation (see 21 CFR 812.2(c) for a description of exempted investigations) must comply with the Investigational Device Exemption (IDE) requirements in 21 CFR part 812 in order to be exempt from many requirements otherwise applicable to medical devices. Instead of being labeled IUO, they must be labeled



*Contains Non-binding Recommendations*

## **B. Distribution Practices that are Inconsistent with RUO/IUO Designations**

A product's intended use refers to the "objective intent" of those legally responsible for labeling the product<sup>8</sup>, which may be determined by looking at the totality of circumstances surrounding the distribution of the article.<sup>9</sup> Overt expressions by the manufacturer, such as those present in labeling and advertising, may be sufficient to show determine that an IVD product is in appropriately labeled RUO or IUO, when such expressions demonstrate that the device is actually intended for clinical use despite the RUO or IUO labeling. Other evidence of the intended use of a product could include the design of the product, other statements by the manufacturer about the device, and how the device is sold and distributed by or on behalf of the manufacturer. The following are examples of evidence of intended uses that, depending on the totality of the circumstances surrounding the distribution of the article, would appear to conflict with RUO or IUO labeling:

- Written or verbal statements in any labeling, advertising, or promotion of the IVD product by or on behalf of the manufacturer, including any performance claims, instructions for clinical interpretation, clinical information, product names, or descriptors that claim or suggest that the IVD product may be used for any clinical diagnostic use, including a clinical investigation subject to part 812. This may include workshops or presentations that describe clinical uses of products labeled RUO or IUO that do not include appropriate statements and warnings about the research or investigational nature of the products;
- Written or verbal statements in any labeling, advertising, or promotion of the IVD product by or on behalf of the manufacturer that suggest that clinical laboratories can validate the test through their own procedures and subsequently offer it for clinical diagnostic use as a laboratory developed test.
  - Solicitation of business from clinical laboratories; for example, a manufacturer who produces only products labeled RUO whose sales force makes routine calls to clinical laboratories that do not perform research or clinical studies may be viewed as demonstrating its intent that its products be used for clinical purposes.
- Provision of certain types of specialized technical support<sup>10</sup> (e.g., assistance in performing clinical validation) to clinical laboratories.

---

"CAUTION—Investigational device. Limited by Federal (or United States) law to investigational use." 21 CFR 812.5.

<sup>8</sup> For the purposes of this guidance document, the term "manufacturer" 21 CFR 806.2(g) is taken as synonymous with "persons legally responsible for the labeling of devices" 21 CFR 801.4. The term "manufacturer" is used as a convenience throughout the guidance.

<sup>9</sup> See 21 CFR 801.4.

<sup>10</sup> Note: FDA is not referring here to generic maintenance support or software updates for an RUO or IUO IVD product.

*Contains Non-binding Recommendations*

Other practices, though not themselves in conflict with RUO or IUO labeling, may support a finding of a conflicting intended use when accompanied by behavior described above. For example, when there is a past history of distribution of a product intended for clinical diagnostic use as an analyte specific reagent (ASR), and the product is now labeled as RUO or IUO, without any change in distribution practices such as advertising to and solicitation of business from clinical laboratories, the “new” RUO/IUO labeling is likely to be inconsistent with the intended use of the manufacturer.

Other practices may or may not indicate an intended use that is consistent with RUO/IUO labeling, depending on the context. For example:

**1. Instructions for use for an IVD product labeled RUO or IUO**

FDA may consider all labeling for the product, including the content of the instructions for use and descriptive language in package inserts provided with the product as evidence of intended use.

In certain circumstances, such as when the use of an IVD product labeled for research use only is limited to use in the conduct of laboratory research that is unrelated to the development of IVDs, providing instructions for correctly using the product in a research manner (for example, mixing proportions, incubation times, storage conditions, etc.) would be considered to be consistent with research use only labeling. However, inclusion of clinical interpretive information, discussion of clinical significance, or other indications of clinical applicability included with any IVD products labeled for research use only would suggest that such products are not intended for research use only, but rather that they are intended for non-research clinical diagnostic purposes. FDA would consider the provision of such information as evidence of an intended use that would appear to conflict with research use only labeling, and requires compliance with all applicable device requirements under the FD&C Act.

FDA believes that those products that are being distributed for use in the research phase of IVD development may be unlikely to need instructions for use, as such products are still in their formative stages, and provision of instructions for using such products may not always be necessary. If basic instructions for use are needed in order to properly configure or use the device in the research phase of development, provision of these may be viewed as consistent with RUO labeling. For IVD products labeled IUO that are the subject of a clinical investigation by a sponsor other than the manufacturer, it is acceptable (and perhaps necessary) for the manufacturer to provide instructions for use to the sponsor of the study using the format described in 21 CFR 809.10(b).

**2. Validation and verification of clinical diagnostic testing using IVD products labeled RUO or IUO**

FDA views the activities of a manufacturer that aid the clinical laboratory in validation

*Contains Non-binding Recommendations*

or verification of a test that incorporates RUO or IUO labeled IVD products as evidence of the manufacturer's intended use. If the manufacturer of an IVD product labeled RUO or IUO were to assist in the validation or verification of the performance of a test for clinical diagnostic use that uses its RUO or IUO labeled IVD, that assistance would be considered to be evidence of a non-research or non-investigational intended use. FDA would consider such evidence along with the totality of the circumstances.

In contrast, the manufacturer of an appropriately labeled RUO or IUO device may provide support services such as general repair or maintenance, and general non-diagnostic use-specific technical support, because, in general, these would not constitute evidence of a non-research or non-investigational intended use.

FDA recommends that manufacturers assess the totality of the circumstances surrounding the sale and distribution of their RUO and IUO labeled IVD products to ensure that they are not engaging in practices that conflict with their labeling.

## **C. Other Relevant Practices**

### **1. Use of a “certification program”**

The totality of the circumstances surrounding the distribution and use of an RUO or IUO product should be considered when assessing its intended use. User certification programs, where users certify that they will not use RUO/IUO products in a manner inconsistent with the labeling, would be viewed as one factor to consider when assessing these circumstances. However, the existence of a certification program alone would not relieve manufacturers from their responsibilities to ensure that their labeling and distribution practices for RUO/IUO products are consistent with the product's RUO/IUO label.

### **2. Software labeled RUO or IUO**

Software that is a stand-alone IVD product, or a component of or an accessory to another IVD product, which is labeled for research or investigational use only, may be distributed for research or investigational use to entities conducting research or investigations with the software.

## **V. FDA's Compliance Approach**

Manufacturers must comply with all applicable requirements under the FD&C Act and FDA regulations for those IVD products that are intended for use in clinical diagnostic applications. For devices that are not used in research or investigation, these requirements generally include registration of the manufacturer and listing of the device(s), compliance with current Good Manufacturing Practices, and reporting of adverse events, among other general controls. There are also specific requirements for various device types, for example,

*Contains Non-binding Recommendations*

analyte specific reagents. *See* 21 CFR 809.10(e), 809.30, & 864.4020. While some IVD products, including some analyte specific reagents, are exempt from premarket notification, other products require premarket clearance or approval. Where the appropriate regulatory pathway is unclear, manufacturers are encouraged to discuss the matter with FDA.

When determining whether non-compliance with statutory and regulatory requirements warrant a regulatory and/or enforcement action, FDA intends to consider the totality of the circumstances concerning a manufacturer's sale and distribution of a product labeled as RUO or IUO.

In general, if evidence shows that an IVD product is inappropriately labeled RUO or IUO, and that the product does not qualify for an investigational device exemption under 520(g) of the Act, and is not cleared, approved, or 510(k)-exempt, the device would be misbranded under sections 502(a) and 502(o) of the Act, 21 U.S.C. 352(a), 352(o), and adulterated under section 501(f) of the Act, 21 U.S.C. 351(f).



# REFERENCE 2

19 CFR 142.3, 142.16, 142.22, 142.24

ABI CERTIFIED

## 27. CERTIFICATION

28. CBP USE ONLY

☐ OTHER AGENCY ACTION REQUIRED NAMELY:

SIGNATURE OF APPLICANT

## PHENOMENO

121

DATE \_\_\_\_\_

07/28/15

☐ CBP EXAMINATION REQUIRED

☐ ENTRY REJECTED BECAUSE

29. BROKER OR OTHER GOVT. AGENCY USE \_\_\_\_\_

02	FDA HOLD	07/27/15
14	FDA DOCUMENTS REQUIRED	07/27/15
02	FDA HOLD	07/28/15
14	FDA DOCUMENTS REQUIRED	07/28/15

DELIVERY AUTHORIZED.	SIGNATURE	DATE
----------------------	-----------	------

CBP Form 3461 (10/09)

## CUSTOM INVOICE

242-243

<b>SHIPPER</b> [REDACTED]		<b>INVOICE NO &amp; DATE</b> [REDACTED]		<b>EXPORTERS REF</b> [REDACTED]	
<b>CONSIGNEE</b> [REDACTED]		<b>Buyers Order No:</b> [REDACTED]			
<b>DEA Number:</b> [REDACTED] <b>Phone Number:</b> [REDACTED]		<b>PRE CARRIAGE BY</b> [REDACTED]		<b>PLACE OF RECEIPT OF PRE CARRIER</b>	
<b>VESSEL / FLIGHT NO</b>		<b>PORT OF LOADING</b> [REDACTED]		<b>COUNTRY OF ORIGIN</b> [REDACTED]	
<b>PORT OF DISCHARGE</b>		<b>FINAL DESTINATION</b> Huntsville, Texas		<b>COUNTRY OF FINAL DESTINATION</b> USA	
<b>DESCRIPTION OF GOODS MARKS &amp; NO/ NO &amp; KIND OF PACKAGE CONTAINER NO:</b>		<b>QUANTITY</b>		<b>AMOUNT per unit (USD)</b>	
Thiopenta Sodium USP 1gm Vial		1000 Vials		[REDACTED]	
Value Given For Custom Purpose: [REDACTED]				[REDACTED]	
Declaration: We declare that this invoice shows the actual price of the goods Described and that all the particulars are true and correct		<b>SIGNATURE / DATE</b>		[REDACTED]	

**TX002**

**Explanation for the Legitimate Use of Thiopental Being Imported Under 21 U.S.C. § 952**

This product is being imported for use by the [REDACTED] law enforcement activities. The product complies with federal statutory and regulatory requirements. The [REDACTED] will not use this product for activities other than law enforcement activities.

[REDACTED]  
June 8, 2015  
Date



# QUALITY CONTROL DEPARTMENT **CERTIFICATE OF ANALYSIS-FINISHED PRODUCT**

Product Name			
Generic Name	Thiopental Sodium for injection USP		
Manufactured by:		Mfg. Date.	06/15
		Exp. Date.	05/17
Batch No.		Date Sampled.	10/06/15
Batch Size.		Qty Sampled.	40 Units
Sampled by.		Release Date.	24/06/15
Specification	USP specification	A.R. No	

S No	TEST	SPECIFICATION	RESULT
1	Description	Yellowish to white powder filled in colorless glass vials.	Yellowish to white powder filled in colorless glass vials.
2	Identification	Should be positive for Thiopentone Sodium	Complies
3	Average filled wt.	1.095 g $\pm$ 10 %	1.0210 g
4	Reconstituted Solution	When reconstituted with SWFI solution is clear & free from Suspended matter.	Complies
5	pH	10.2-11.2	10.6
6	Particulate Matter	Should be free from particulate matter when examined visually	Complies
7	Residual solvent s	Meets the requirements	Complies
8	Appearance of Solution	10.0 % w/v Test solutions in carbon dioxide free water is clear than reference standard solution.	Complies
9	Bacterial Endotoxin	Not more than 1.0 EU/ mg	Less than 1.0 EU/mg
10	Sterility Test	Should be sterile	sterile
11	Assay: Each vial contains:	Result	Limit
	Thiopentone Sodium USP	989.1 mg	930. mg to 1070 mg

Remarks: The above Sample Complies as per USP Specification.

Analyzed by	Checked by	Approved by (C Manager)
Sign		
Date	24/06/15	

001 DFW 52866343

001-52866343

Shipper's Name and Address		Shipper's Account Number		Not Negotiable <b>Air Waybill</b>		Issued by	
Consignee's Name and Address		Consignee's Account Number		Copies 1, 2 and 3 of this Air Waybill are originals and have the same validity.			
It is agreed that the goods described herein are accepted in apparent good order and condition (except as noted) for carriage SUBJECT TO THE CONDITIONS OF CONTRACT ON THE REVERSE HEREOF. ALL GOODS MAY BE CARRIED BY ANY OTHER MEANS INCLUDING ROAD OR ANY OTHER CARRIER UNLESS SPECIFIC CONTRARY INSTRUCTIONS ARE GIVEN HEREON BY THE SHIPPER, AND SHIPPER AGREES THAT THE SHIPMENT MAY BE CARRIED VIA INTERMEDIATE STOPPING PLACES WHICH THE CARRIER DEEMS APPROPRIATE. THE SHIPPER'S ATTENTION IS DRAWN TO THE NOTICE CONCERNING CARRIER'S LIMITATION OF LIABILITY. Shipper may increase such limitation of liability by declaring a higher value for carriage and paying supplemental charge if required.				Accounting Information			
Airport of Departure (Addr. of First Carrier) and Requested Routing DALLAS FT. WORTH				Reference Number		Optional Shipping Information	
To		By First Carrier		Routing and Destination		Declared Value for Carriage	
IAH						NVD	
Airport of Destination		Requested Flight/Date		Amount of Insurance		INSURANCE - If carrier offers insurance, and such insurance is requested in accordance with the conditions thereof, indicate amount to be insured in figures in box marked "Amount of Insurance"	
DALLAS FT. WORTH				XXX			
Handling Information - These commodities, technology or software were exported from the United States in accordance with the Export Administration Regulations. Diversion contrary to U.S. law prohibited.							
SCI							
No. of Pieces RCP	Gross Weight	kg	Rate Class	Chargeable Weight	Rate / Charge	Total	Nature and Quantity of Goods (incl. Dimensions or Volume)
1	60L	M		60	75.00	75.00	XXX VACINES NH
3	60		EPX-EXPEDITEFS	NORMAL 80		75.00	
Prepaid		Weight Charge		Collect		Other Charges	
75.00						MYC24.00 SEC6.00 AWC15.00 XBC15.00	
Valuation Charge		Tax		Total Other Charges Due Agent		Total Other Charges Due Carrier	
		7.50				60.00	
Total Prepaid		Total Collect		Signature of Shipper or his Agent			
142.50							
Currency Conversion Rates		CC Charges in Dest. Currency		Signature of Issuing Carrier or its Agent			
1.000000							
For Carrier's Use only		Charges at Destination		Total Collect Charges			

FDA 152

25 JUL 2015

Executed on (date)

at (place)

Signature of Issuing Carrier or its Agent

# REFERENCE 3





FDA  
7/25/15  
RES 2

07/28/2015

7/28/2015 RES 2



Copies 1, 2 and 3 of this Air Waybill are originals and have the same validity.

It is agreed that the goods described herein are accepted in apparent good order and condition (except as noted) for carriage SUBJECT TO THE CONDITIONS OF CONTRACT ON THE REVERSE HEREOF. ALL GOODS MAY BE CARRIED BY ANY OTHER MEANS INCLUDING ROAD OR ANY OTHER CARRIER UNLESS SPECIFIC CONTRARY INSTRUCTIONS ARE GIVEN HEREON BY THE SHIPPER, AND SHIPPER AGREES THAT THE SHIPMENT MAY BE CARRIED VIA INTERMEDIATE STOPPING PLACES WHICH THE CARRIER DEEMS APPROPRIATE. THE SHIPPER'S ATTENTION IS DRAWN TO THE NOTICE CONCERNING CARRIER'S LIMITATION OF LIABILITY. Shipper may increase such limitation of liability by declaring a higher value for carriage and paying supplemental charge if required.

Accounting Information

FDA MICHAEL  
VALENZUELA  
713-214-1440

Reference Number

Optional Shipping Information

07/28/2015

Currency	CHGS Code	WT/VOL		Origin		Declared Value for Carriage	Declared Value for Customs
		PPD	COLL	PPD	COLL		
D	FXX		X			NVD	NCV

FDA 156












7/28/2015 RES 7











7/28/2015 RES 11















7/28/2015 RES 17















7/28/2015 RES 22







7/28/2015 RES 25












7/28/2015 RES 29









7/28/2015 RES 32












PC WGT

20L

07/28/2015






7/28/2015 RES 37









7/28/2015 RES 39































7/28/2015 RES 50


















7/28/2015 RES 57















7/28/2015 RES 63

# REFERENCE 4



UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF COLUMBIA

DONALD EDWARD BEATY, *et al.*,

Plaintiffs,

v.

Civil Case No. 11-289 (RJL)

FOOD AND DRUG  
ADMINISTRATION,

and

U.S. DEPARTMENT OF HEALTH  
AND HUMAN SERVICES,

and

KATHLEEN SEBELIUS, in her official  
capacity as Secretary of the U.S.  
Department of Health and Human  
Services,

and

MARGARET A. HAMBURG, M.D., in  
her official capacity as Commissioner of  
Food and Drugs,

Defendants.

ORDER

(March 27, 2012)

For the reasons set forth in the Memorandum Opinion entered this 27<sup>th</sup> day of March, 2012, it is hereby

**ORDERED** that plaintiffs' Motion for Summary Judgment and Declaratory Relief on Counts I and III [#12] is **GRANTED**; and it is further

**ORDERED** that the defendants' Motion to Dismiss and/or for Summary Judgment [#13] is **DENIED**; and it is further

**DECLARED**, pursuant to 28 U.S.C. § 2201(a), that


1. the foreign manufactured thiopental (or “thiopental”) imported by the importing States (e.g. Arizona, California, South Carolina, Georgia, and Tennessee) is a misbranded drug and an unapproved new drug within the meaning of the FDCA; and
2. as such, this thiopental cannot lawfully be introduced or delivered for introduction into interstate commerce or lawfully be imported into the United States; and
3. defendants’ recent actions allowing such thiopental to enter the United States were each contrary to law, arbitrary, capricious, and an abuse of discretion under the APA; and, in particular,
4. defendants’ January 4, 2011 announcement that they will allow future shipments of such thiopental to enter the United States is contrary to law, arbitrary, capricious, and an abuse of discretion under the APA; accordingly

**IT IS HEREBY ORDERED** that the FDA:

1. immediately notify any and all state correctional departments which it has reason to believe are still in possession of any foreign manufactured thiopental that the use of such drug is prohibited by law and that, that thiopental must be returned immediately to the FDA; and
2. be permanently enjoined from permitting the entry of, or releasing any future shipments of, foreign manufactured thiopental into interstate commerce; and

**IT IS FURTHER ORDERED** that the parties are hereby directed to meet and confer to determine whether further litigation is necessary, or proper, with respect to the remaining count in this Complaint.

**SO ORDERED.**

  
RICHARD J. LEON  
United States District Judge

# REFERENCE 5

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF COLUMBIA

Donald Edward BEATY, Daniel Wayne COOK,  
Eric J. KING, Brett Patrick PENSINGER, and  
Stephen Michael WEST,

Plaintiffs,

v.

FOOD AND DRUG ADMINISTRATION, UNITED  
STATES DEPARTMENT OF HEALTH AND  
HUMAN SERVICES, Kathleen SEBELIUS, and  
Margaret A. HAMBURG, M.D.,

Defendants.

Civil Action No. 1:11-cv-00289 (RJT)

ECF Case

**FILED**

JUN 22 2012

Clerk, U.S. District & Bankruptcy  
Courts for the District of Columbia

**ORDER**


Upon consideration of the Unopposed Motion to Dismiss Count II, Enter Final Judgment, and Make Certain Modifications to the Court's Injunction filed by Plaintiffs in the above-captioned matter, it is this 22 day of June, 2012,

**ORDERED**, that the Motion is GRANTED, and it is further,

**ORDERED**, pursuant to Federal Rule of Civil Procedure 41(a)(2) that Count II of Plaintiffs' First Amended Complaint is dismissed without prejudice; and it is further,

**ORDERED**, that the sentence of the Order dated March 27, 2012 (Dkt. No. 24), stating that FDA is "permanently enjoined from permitting the entry of, or releasing any future shipments of, foreign manufactured thiopental into interstate commerce" is hereby modified to read, "permanently enjoined from permitting the entry of, or releasing any future shipments of, foreign manufactured thiopental that appears to be misbranded or in violation of 21 U.S.C. §§ 355," and it is further,

**ORDERED**, pursuant to Federal Rule of Civil Procedure 54(b) that the Clerk shall enter final judgment disposing of this action in its entirety.

A handwritten signature in black ink, appearing to read "Richard J. Leon", written over a horizontal line.

Hon. Richard J. Leon  
United States District Court Judge



# REFERENCE 6